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Abstract 
Diabetes affects an estimated 29.1 million Americans, with approximately another 1/3 of 
Americans not yet diagnosed. Complications associated with diabetes include heart 
disease, stroke, hypertension, blindness, kidney disease, neuropathy and death. All of 
these complications can be prevented with optimal control of blood glucose levels. 
Advances in technology provide people living with diabetes (PLWD) a multitude of 
treatment options such as continuous subcutaneous insulin infusion (CSII) therapy. 
Unfortunately, sustained improvement in glycated hemoglobin A1c (HgA1c) is not 
always achieved even with this advanced therapy. The purpose of this doctoral project 
was to educate nurses on CSII therapy and promote improved patient compliance, 
knowledge and ultimately improve HgA1c control. This doctoral project is an evaluation 
of an Evidence-Based Quality Improvement Project (EB-QIP) that evaluated  nurse-led 
educational sessions for PLWD using CSII therapy. The integrated theory of health 
behavior change was used to guide the project. The CDC process evaluation model was 
used to evaluate the outcomes of the education sessions. Results showed that patients 
who were instructed by the nurses who took part in the EB-QIP had a reduction in the 
overall HgA1c by an average of 1.1 points 3-months post-education. The project 
promotes positive social change through establishing the effectiveness of an EB-QIP that 
focused on the use of education on CSII therapy in improving outcomes for patients 
living with diabetes.  
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Section 1: Nature of the Project 
 Introduction                                                                  
Type 1 and Type 2 diabetes are chronic conditions that have experienced 
exponential growth worldwide (Rowley & Bezold, 2012). The prevalence of diabetes has 
increased in the United States, from 1.6 million in 1958, accounting for 0.9% of the 
population, to 23.4 million in 2015, accounting for 7.4% (CDC, 2017). The United States 
has become the epicenter of “supersized” with the explosion of fast food and subsequent 
rise in obesity (Spurlock & Spurlock, 2004). This, in addition to sedentary lifestyles, has 
led to the dramatic increase in diabetes and other associated chronic health conditions. In 
the United States, the prevalence of diabetes among the adult population ranges between 
5.8% and 12.9%, accounting for approximately 14% of all health care expenditures, or 
$245 billion (McCulloch, 2016). 
Type 2 diabetes (T2D) is expected to increase approximately 64%, from 19.1 to 
53.1 million, by 2025 (Rowley & Bezold, 2012); worldwide T2D is expected to increase 
to approximately 415 million, with an annual economic impact close to $500 billion. The 
United States spends nearly double in health care expenses per capita compared to 
countries such as Germany, Canada, Denmark and France (Zhang et al., 2010). The 
increasing cost of treating chronic diseases such as diabetes is causing an economic crisis 
in the United States. The economic backlash is not only hurting the United States fiscal 
pocketbook but is becoming a financial hardship for individuals and families. The cost of 
annual health insurance premiums for the average American family ($17,545) is close to 
the gross yearly income of a full-time minimum wage worker, (KFF, 2015). 
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Without sustained HgA1c normalization, complications are likely, such as 
cardiovascular/cerebrovascular disease, renal impairment, retinopathy, and peripheral 
neuropathy (McCulloch, 2016). These complications can present silently until end-organ 
or vessel damage manifests. With the traditional use of multiple daily injections of insulin 
that are required to promote optimized glycemic control, personal compliance is critical. 
Multiple daily injection (MDI) therapy requires approximately 5 to 6 injections daily, 
along with frequent finger pricks to monitor blood glucose levels (Mayo Clinic, 2017). 
Also, MDI therapy brings with it a high risk of hypoglycemia, as exogenous insulin has a 
slower rate of absorption when compared to the normal physiology of the pancreas in a 
person who is nondiabetic (McCulloch, 2016). 
Modern medicine, especially technological advances and treatment modalities, 
has experienced remarkable advances. Continuous subcutaneous insulin infusion (CSII) 
therapy, also known as insulin pump therapy, has greatly improved the quality of life for 
many people living with diabetes requiring insulin therapy. As this therapy was designed 
to improve glycated hemoglobin (HgA1c) levels in people living with diabetes (PLWD) 
requiring insulin therapy, it is becoming evident that this reduction is only short-term, as 
HgA1c levels over time begin to increase (Nixon, Folwell, &Pickup, 2014). The increase 
in HgA1c levels may be associated with knowledge deficiency, poor patient compliance 
with the use of this sophisticated technology, a lack of sufficient patient education 
focusing on CSII technology, or the interaction between the patient and health care 
provider (Nixon, Folwell, & Pickup, 2014). As the tasks related to CSII technology can 
be quite intricate, basic functions are the focus of the training when CSII therapy is 
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initiated, leaving PLWD lacking a more in-depth understanding of the use of their insulin 
delivery system. So, the decline in HgA1c levels after initiation of CSII therapy may be 
not be linked solely to one cause, but a combination of many causes.  
The purpose of this doctoral project was to evaluate the outcomes of a quality 
improvement project (QIP) specific to PLWD using CSII therapy. The QIP consisted of 
three 45-minute education sessions to improve the knowledge and the confidence of 
PLWD in engaging in self-management to stabilize HgA1c levels. Secondary, 
deidentified data, was used to determine the effectiveness of the QIP and included 
aggregate serum HgA1c levels prior to initiation of the QIP and aggregate serum HgA1c 
levels three months post QIP.   
Local Context for Gap-In-Practice 
Breakthroughs in technology, such as CSII therapy, are changing how PLWD 
manage this disease. Although the CSII technology will not reduce the number of PLWD, 
the complications related to diabetes can be minimized. The research specific to the 
effectiveness of CSII therapy is mixed, however. Bode (2010) posits achieving maximum 
CSII therapy effectiveness requires continued patient education, in addition to the 
traditional cross-sectional and basic education received at the initiation of CSII therapy. 
Without tailored longitudinal guidance to learn strategies for glycemic control 
(Bergenstal et al., 2013), the typical PLWD will not realize the benefits offered by the 
CSII technology.  
CSII technology provides different data entry options that are person-specific. 
This facilitates the insulin that mimics the function of pancreas, delivering both basal and 
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bolus insulin. Without understanding the basic-level options through experience and 
continued education, the more advanced tasks available with the CSII technology are not 
realized.  As Bergenstal et al. (2013) explain, the knowledge deficit reduces the ability of 
a provider to collaborate with the PLWD to make safe clinical decisions when adjusting 
CSII data.  
According to Bergenstal et al. (2013), analysis and visualization of pertinent 
standardized glucose data by providers also plays a contributing role in poor glycemic 
control among CSII users. Analysis of the data provided by the CSII device is critical in 
calculating appropriate insulin administration. This data weighs heavily on the precise 
computation of insulin needs, carbohydrate intake, sleep/wake cycles, and glucose levels. 
To program the CSII technology to deliver the correct insulin, the provider must have 
expert knowledge in analyzing what is visualized on the charts and graphs that are 
furnished with each CSII download (Medtronic, 2009). This knowledge, although not 
expert, should be understood by the user of the CSII technology at least minimally to 
recognize the importance of correct data input. This is a vital reason patient education is 
so relevant in optimizing glycemic control.  
Local Relevance.  
The State of Arizona has a population of 1,796,000, with 682,071 diagnosed with 
diabetes, which is 12.5% of the adult population (American Diabetes Association [ADA], 
2015). Prediabetes, higher than normal blood glucose levels (70 – 100), accounts for 
37.5% of the adult population, with an estimated 34,000 newly-diagnosed diabetics in 
Arizona yearly (ADA, 2015). Between 1995 and 2010, there was an 80% increase in 
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people diagnosed with diabetes in Arizona, while it is theorized that one-third remain 
undiagnosed (Humble & Tormala, 2011).  In 2011, there were 390,000 people in Arizona 
reported to have diabetes (Humble & Tormala, 2011); four years later the diabetic 
population almost doubled to the estimated 682,071 people diagnosed with diabetes in 
Arizona (ADA, 2015). An estimation of those undiagnosed in the State of Arizona is 
172,000 (ADA, 2016).  
In 2006, there were 1,755 per 100,00 diabetes-related hospitalizations in Arizona, 
accounting for 170 more hospitalizations than other Western states (Humble & Tormala). 
The total direct medical expenses associated with treatment of diabetes in the State of 
Arizona was estimated at $4.9 billion in 2012, with an additional $1.5 billion for indirect 
costs associated with diabetes. Nationally, the total estimated cost associated with the 
diagnosis of diabetes in 2012 is $245 billion; $176 billion in direct medical costs and $69 
billion in indirect costs.  Reported costs associated with diabetes prevention and 
education in the State of Arizona in 2016 provided by the Division of Diabetes 
Translation at the Centers for Disease Control and Prevention (CDC) was $1,941,335. In 
2015, the National Institute of Diabetes and Digestive and Kidney Diseases at the 
National Institute of Health provided funding in the amount of $10,085,465 to be used for 
research projects specific to diabetes in the State of Arizona (ADA, 2016).      
The Diabetes Clinic (a pseudonym) is located in a large southwestern state with a  
patient population consisting of Native-Americans, Hispanics, Asians, non-Hispanic 
Whites, and African-Americans. Diabetes statistics vary across the ethnic groups. For 
example, diabetes affects approximately 16.1% in the Native-American population, 
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followed by 12.6% of African-Americans, 8.4% Asians, 11.8% Hispanics, and 7.1% non-
Hispanic whites (Humble & Tormala, 2011). According to the Center for Disease Control 
and Prevention (CDC) Report in 2011, the Native-American community in Arizona 
accounts for 5% of the population at approximately 319,600 people.  
Worldwide, 415 million people have been diagnosed with diabetes, in addition to 
an estimated 193 million people that are either unaware of being diabetic or have not yet 
been diagnosed (Chatterjee, Khunti & Davies, 2017). In 2015, diabetes was placed as the 
sixth-leading cause of disability, creating a global economic burden estimated at $825 
billion (Chatterjee, Khunti & Davies, 2017). In the United States, the economic burden of  
managing diabetes is approximately $245 billion yearly (CDC, 2014). Improving diabetes 
care with the promotion of CSII therapy in PLWD is paramount for decreasing the 
chronicity of diabetes and its complications. 
Significance to Nursing   
Health care is advancing in the United States, offering nurses more active roles in 
improving patient care through implementing evidence-based practices. Nurse-led 
education has become important in chronic disease management (Levich, 2011). Specific 
to diabetes, nurses can positively impact social change with respect to increasing the 
effectiveness of insulin therapy by reducing knowledge deficits and increasing self-
management skills (Levich, 2011).    
Inadequate management of diabetes can lead to increased complications, 
decreased quality of life, and large financial expenditures. By 2020, chronic diseases will 
account for an estimated three-quarters of the disease burden globally, consisting of an 
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estimated 60% from diabetes alone, specifically T2D and cardiovascular disease. (Day & 
Brown, 2014). With the chronic disease burden growing, nurses are ideally positioned in 
organizations and educationally prepared to provide the necessary longitudinal education 
to advance self-management skills by decreasing the knowledge deficit.  
According to Levich (2011), nurses should lead the agenda to engage in long-term 
person-specific education to enhance the management of PLWD using CSII technology. 
This project is particularly important as nurses need to also engage in outcomes 
evaluations for their work. For PLWD using CSII therapy for glycemic control, a nurse-
led education program can potentially increase experiential knowledge through the use of 
technology and increase self-management by reducing knowledge deficits. The purpose 
of this doctoral project was to evaluate the impact a nurse-led education program has on 
improving the knowledge deficit and self-management of diabetes.  
Purpose Statement 
Gap-in-Practice 
 For PLWD, CSII therapy provides a convenient, targeted, and tailored means for 
timely insulin infusions to rapidly respond to changes in blood glucose levels. However, 
there is a gap in nursing practice specific to knowledge deficits when PLWD utilize the 
treatment modality and achieve suboptimal reductions in HgA1c levels. Jayasekara, 
Munn, and Lockwood (2011) found that PLWD need continued education and training 
with comprehensive advice by experts to successfully use CSII therapy. Wu et al. (2013) 
reported that, with continued education and training by skilled professionals, PLWD had 
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significant reductions in HgA1c levels (p < 0.001), improvements in self-efficacy (p 
<0.001), and increased self-care (p <0.001). 
The purpose of this doctoral project was to evaluate the impact of a nurse-led 
education program on glycemic control for PLWD using CSII technology. The nurse-led 
education program consisted of three 45-minute sessions focused on advanced 
technological training specific to CSII therapy, and the development of self-management 
skills. The hypothesis was that effective multi-session education can reduce knowledge 
deficits, improve self-efficacy, and promote self-management. The increased use of CSII 
therapy for intensive insulin treatment for PLWD is an appropriate option for many; 
however, not every PLWD is a good candidate for this treatment modality. With 
technological advancements it is imperative that the appropriate education, geared toward 
specific patient populations, be designed to promote the best possible outcome. Use of 
CSII therapy in PLWD over the next decade is expected to double, according to Saboo 
and Talaviya (2012). This expected growth should prompt the medical community to 
enhance the use of CSII therapy with extended educational sessions that promote self-
management skills along with improving knowledge deficits correlated with the correct 
use of CSII technology. 
There is inconsistent success with CSII therapy reported in the literature as 
demonstrated by Chamberlain and Gilgen (2014), who conducted a single-arm study that 
included 16 T1D and 12 T2D, concluding that patients’ perceptions of the usability of 
CSII technology greatly affected the success of the therapy. The OpT2mise RCT study 
suggested that there was much greater variability in the T2D population versus the T1D 
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population (Aronson et al., 2014). Conget et al. (2016) performed a follow-up study that 
concluded suboptimal controlled T2D had significant improvement in HgA1c levels with 
the use of CSII therapy.  Seven contributory factors were identified, including: 
1. Patient tolerance and/or intolerance to insulin and therapy; 
2. Biological changes to the patient resulting from age and/or gender; 
3. Endocrine system function; 
4. Patient lifestyle and stress levels; 
5. Provider interaction and/or monitoring intervals; 
6. Sensory-Augmented Pump Therapy (SAPT); and. 
7. CSII technological shortfalls. 
On quarterly follow-up assessments of PLWD utilizing CSII therapy at the 
diabetic clinic, systematic CSII (insulin pump) downloads are performed to evaluate data 
that is input into the insulin pump by the individual using the CSII therapy. This data is 
then used to calculate insulin pump settings in an effort to optimize disbursement of 
insulin and regulation of blood glucose levels. It has been identified, through the review 
of reports generated from the insulin pump download, that consistent blood glucose 
monitoring is suboptimal in many instances. Blood glucose monitoring should be 
performed a minimum of 4 times daily, however, ideal monitoring consists of 5 to 6 
times daily for CSII therapy optimization (Mayo Clinic, 2017). CSII technology provides 
several reports generated through patient interaction with the insulin pump offering 
specific identifying factors that will alert the provider of inadequate use of CSII 
technology. Although CSII therapy promises to provide tighter glucose levels, thus 
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improving patient outcomes, the technology is changing so rapidly that it is theorized that 
PLWD and providers lack the up-to-date knowledge to optimize it. 
Evidence-Based Health Care 
Evidence-based health care formulates and implements treatment plans based on 
current knowledge derived from evidence-based research and expert opinion. The intent 
is to deliver safe, effective care that is patient-specific and promotes positive outcomes. 
The evidence-based health care approach incorporates problem-solving with the most 
current evidence from peer-reviewed research studies, along with advice from a 
knowledgeable clinician, and considers values and preferences of the patient (Fineout-
Overholt, Melnyk, Schultz, 2005). Through a patient-centered, evidence-based approach 
to the management of diabetes, Tricco et al. (2012) found improvement in the 
management of diabetes through quality improvement (QI) strategies. The strategies that 
supported the greatest improvement in HgA1c levels were patient education and the 
promotion of self-management skills guided by health-care professionals (Tricco et al., 
2012). Tricco et al. (2012) demonstrated that, by implementing evidence-based health 
care in the design of interventions that focused on quality indicators, HgA1c levels 
improved; however, when QI strategies focused on targeting both health systems and 
patients, there was even greater improvement in HgA1c levels. 
PICOT Process 
A well-designed EB-QIP begins with recognizing a clinical problem, or situation 
that can be positively changed and/or be improved upon. By structuring a question that 
specifically defines the problem, evidence-based practice can be implemented using a 
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problem-solving approach to the situation (Fineout-Overholt, Melnyk, & Schultz, 2005). 
The PICOT question is a formula designed for nurses to easily categorize the components 
necessary in defining the clinical problem, allowing for strategic organization of details 
and the formulation of a structured problem statement. Through the PICOT process, the 
nurse is able to gather appropriate research evidence and evaluate the evidence before 
implementing it into practice. Through the evaluation process, interventions will be 
applied that best fit the clinical problem and the problem statement. Interventions are 
developed that best fit the population affected, problem identified, and place in which the 
intervention will be implemented. Evidence-based research is employed in this process to 
promote improved patient outcomes. 
Guiding Practice Focused Question  
How will nurse-led educational sessions for PLWD using CSII therapy impact 
knowledge deficit and HgA1c levels?  
Response to the Gap-in-Practice 
CSII therapy, otherwise known as insulin pump therapy, has been in use for over 
50 years (American Association of Diabetes Educators [AADE], 2014). According to the 
AADE (2014), CSII therapy provides improved quality of life with a less restricted 
lifestyle, along with improvement in glycemic control. The success of CSII therapy is 
determinant on careful assessment of PLWD, including physical and psychological 
factors that are key features in identifying a person’s ability to successfully overcome the 
challenges of insulin pump technology (AADE, 2014).  
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The technology of CSII therapy can be very intricate and difficult to understand, 
especially for the novice. Also, at the initiation of CSII therapy, many features of the 
insulin pump are reviewed, which can be daunting for many people. There appears to be 
a gap in the depth of knowledge and use of CSII therapy for PLWD utilizing this 
treatment modality. This has become evident in the reports that are generated through the 
database of each insulin pump at the diabetes clinic identifying noticeable gaps in data.  
The information provided by the insulin pump allows the clinician to view daily 
interaction with the insulin pump by the user, recognizing gaps in proper operation.  
CSII therapy provides continuous insulin infusion that is set by a provider 
delivering basal insulin throughout the day (Saboo. & Talaviya, 2012). However, as 
recognized by the AADE (2014), patients have the responsibility of routinely checking 
blood glucose levels to promote glycemic control. When there is missing information, 
such as blood glucose levels and carbohydrate values, safe adjustments to the insulin 
pump cannot be made, thus poor glycemic control continues. CSII therapy is only as 
good as the user’s ability to furnish the appropriate information and enter it into the 
insulin pump.  
Nature of the DNP Project 
Project Sources of Evidence 
The evidence to support this program evaluation was derived from a secondary 
data analysis consisting of aggregate serum HgA1c values 3 months prior to the initiation 
of the QIP and 3 months after the conclusion of the QIP, along with secondary data 
extracted from the Adherence Reports relevant to the evaluation. This secondary data was 
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made available from the diabetes clinic for the evaluation of the QIP.  No identifying 
patient information was made available to the Doctoral Student performing the 
evaluation.   
Project Method 
All participants in the QIP were PLWD requiring insulin through CSII therapy 
and were patients at the diabetic clinic where the QIP took place. This is an evaluation of 
patient educational sessions. Mandatory participation in three 45-minute educational 
sessions was determined to be appropriate in gathering necessary information for the 
evaluation. Each educational session was participant-specific, identifying areas of need 
for advanced training in CSII therapy through review of the participant’s insulin pump 
download reports with each session. Behavioral data located on the Adherence Report 
was provided by the site to the evaluator (the DNP student) void of any participant 
identifying information upon evaluation of the QIP, allowing for a detailed understanding 
of the participant’s adherence according to indices of glucose measurements, bolus 
events, and insulin pump activities (Medtronic, 2009). 
Each session began with review of the previous sessions’ learning objectives and 
continued with further education about each category in the Adherence Reports. This 
selective focus on each category provided the participants a closer observation of their 
own behaviors regarding the use of their insulin pump and how their behavioral data 
affected their blood glucose levels. Participants were provided detailed educational 
packets that recapped the material covered with each session. Each participant was 
educated on all categories of the insulin pump reports to become familiar with the data 
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derived from the download, and the importance of this data in the improvement of 
glycemic control. All participants participated in three sessions.  
Project Pathway 
The purpose of this doctoral project was to evaluate the outcomes of an 
educational program specific to PLWD using CSII therapy in a diabetic clinic, and to 
identify whether advanced education would provide improvement in HgA1c levels and 
self- management skills focal to CSII use.  
Significance 
Improved clinical outcomes for PLWD are achieved with stabile maintenance of 
normal to near-normal glycemic control (Pozzilli et al., 2016). There are many factors 
that affect normal to near-normal glycemic control. It was the purpose of this project to 
identify these factors, and to evaluate the impact of education on HgA1c and compliance. 
Without normalization of blood glucose levels, chronic conditions can manifest, such as 
diabetic peripheral neuropathy and diabetic retinopathy. Grenell and Turner (2016) 
estimated 47% of patients with diabetes will eventually develop peripheral neuropathy. 
Approximately 50% to 75% of non-traumatic amputations are related to diabetic 
peripheral neuropathy (Grenell & Turner, 2016). This project will analyze the outcomes 
of an EB-QIP aimed to increase the knowledge and skills of the PLWD in the managing 
glycemic control with CSII therapy. 
Stakeholder Analysis 
The most evident stakeholders in this process were PLWD utilizing CSII therapy; 
however, the director of the clinic, as well as the nurse practitioners that provide care to 
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the patients at the clinic were contributing stakeholders, in that their depth of 
understanding the technology of CSII therapy would promote improved patient 
outcomes. Family and friends of PLWD utilizing CSII therapy were also stakeholders, in 
that, through their continued support and encouragement, they could positively advocate 
for the advancement of knowledge needed to continue to improve lifestyle and overall 
health.  
 It is evident in the literature that, with the normalization of HgA1c and reduction 
in the variability of glucose levels, a decline in the complications associated with diabetes 
i.e., microvascular and macrovascular should be seen. The incidence of lower limb 
amputations is 46.1 to 9600 per 105 (Moxey et al., 2011); the Diabetes Control and 
Complications Trial DCCT/Epidemiology of Diabetes Interventions and Complications 
(EDIC) study found that intensive glycemic control reduced fatal and nonfatal 
cardiovascular disease and stroke by 57 percent (McCulloch, 2016). The reductions in 
these catastrophic complications would lead to less time off of work, overall improved 
health and wellness, and economic status for PLWD. 
Quality of life for PLWD and their family members would improve with the 
decrease in complications associated with diabetes. Adriaanse et al. (2015) found that 
maintaining a good quality of life is a pertinent goal to be set with T2D, in that it 
improves a person’s perspective about their well-being socially, physically and mentally. 
The complications associated with diabetes grossly determine the quality of life in PLWD 
(Adriaanse et al., 2015).  
16 
 
Family members often care for loved ones with chronic illness and, with reforms 
in the U.S. health care system, this is becoming more progressive over time (Lim & 
Zebrack, 2004). Lim & Zebrack (2004) found through a literature review that, when 
caregivers experienced stress caring for a family member, this equated to the caregiver 
appraising themselves as lacking in self-efficacy, creating high levels of caregiver 
depression. With reduction in HgA1c levels in PLWD, chronic conditions and 
complications from diabetes can be prevented, alleviating family members from caring 
for a chronically ill loved one.  
The diabetic clinic that performed the QIP, dependent on the evaluation, may 
experience a positive impact from addressing this local problem. Uncontrolled diabetes, 
as discussed previously, is associated with a number of chronic conditions associated 
with the neurovascular, cardiovascular, and renal systems. An increase in patient 
population may be experienced related to the positive outcomes the participants 
experience, lending to primary care providers referring more patients to the clinic for 
treatment of diabetes.  
Contributions to Nursing Practice 
 This doctoral project promotes continued evidence-based projects and translation 
of evidence to stimulate continued education for diabetes and chronic disease states. This 
project was geared to identify the gap not only in practice, but in the significance of 
nursing’s role in the translation of evidence-based quality improvement projects into the 
format of education at a level that PLWD can understand and apply to their everyday 
lives. Technology is rapidly growing, necessitating continued hands-on training of these 
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variable technological gadgets to promote the optimization of the devices, therefore 
providing the best outcomes. Using the basic mechanisms of these intricate devices is 
wasting the depth of technology that is designed to enhance the quality of life, and it is a 
failure of the medical community when PLWD use such technology in the most basic 
fashion. 
 This doctoral project evaluated another level of education that nurses can provide 
to PLWD utilizing CSII technology that promotes optimization of glycemic control, 
reducing known complications associated with uncontrolled diabetes.  
Transferability of Knowledge  
Identifying the gap in practice with CSII technology and diabetic self-
management skills, future nursing projects can continue identifying specialized arenas in 
health in which CSII technology can be used. Improving diabetic self-management skills 
can also parlay into other chronic conditions, educating a multitude of patient populations 
on self-management skills and the promotion of positive outcomes. One area of interest is 
applying CSII technology and the initiation of this modality in people who suffer from 
Addison’s disease. CSII technology could be used to provide continuous cortisol through 
the advanced technology that CSII therapy provides.  The understanding of technology, 
and using it to its full potential, is critical in quality of life as well as positive outcomes. 
Nursing research on patient safety is profoundly important, as is linking the appropriate 
tools to the knowledge needed to be successful. 
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Implications for Positive Social Change 
There is limited research focusing on patient education geared toward CSII 
technology and future advancements associated with this therapy. It is important for 
PLWD who require CSII therapy to thoroughly understand the technological aspect of 
this treatment and acquire knowledge to promote improvement in glycemic control. It is 
believed that, with further education that is person-specific to diabetes and utilizing 
complex functions associated with CSII therapy, there will be improved compliance and 
a reduction in complications associated with uncontrolled diabetes. With the reduction in 
complications of diabetes, costs associated with treatment will be positively affected, 
along with quality of life, for those diagnosed with the disease. 
Summary 
Normalizing HgA1c levels in PLWD requiring insulin therapy promotes better 
patient outcomes by decreasing morbidity and mortality rates, as well as minimizing the 
impact of socioeconomic and quality of life issues. With normalized glycemic control, 
PLWD will experience a reduction in the negative effects of diabetes such as 
nephropathy, neuropathy, and retinopathy, along with cardiovascular problems. 
Improving outcomes for PLWD with education can enhance quality of life for 
PLWD and family members. As I have worked with this population, it has become 
apparent that there is a gap in nursing and the promotion of education to improve self-
management and technological skills of those PLWD utilizing CSII therapy. Upon 
evaluation of this QIP, I developed a clearer insight on the gap in nursing, education and 
normalization of HgA1c levels. 
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Section 2: Background and Context 
Introduction 
The diabetes clinic that performed the QIP estimates that over half of its patients 
are diabetics, and new diabetic patients are being referred to this clinic on a daily basis. It 
is estimated that about a quarter of the PLWD that are seen in this diabetic clinic utilize 
CSII therapy. When oral glycemic agents fail to control blood glucose levels in T2D, 
insulin therapy becomes the mainstay of treatment. For T1D, insulin is the only avenue of 
treatment related to the destruction of pancreatic beta cell production (McCulloch, 2016). 
With the administration of insulin, MDI therapy used to be the only avenue for PLWD to 
control blood glucose levels. MDI therapy entails correct calculation of carbohydrate 
intake, as well as blood glucose levels, along with the administration of insulin at specific 
times throughout the day based off of these calculations. Compliance with MDI therapy 
can become a significant barrier to the normalization of blood glucose levels associated 
with the multiple finger sticks required daily, averaging four to six times, to obtain 
accurate calculations, along with three to four daily injections of insulin daily.  
In 1963, Dr. Arnold Kadish invented the first portable insulin pump; more than 10 
years later, in 1976, Dean Kamen designed the first wearable insulin pump (Ghazanfar et 
al., 2016); also known as CSII therapy. Over the past 40 years, CSII therapy has 
advanced as researchers race to develop the artificial pancreas. These new technologies 
are proving to have an impact on glycemic control in relation to reducing the number of 
injections PLWD have to administer through the day with MDI therapy. CSII therapy is a 
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promising advancement in treatment for diabetes, reducing the complications associated 
with cardiovascular disease, neuropathy and nephropathy, and cholesterol profiles.  
In the diabetic clinic where the QIP took place, a large majority of PLWD 
initiating CSII therapy experienced improvement in HgA1c levels. Unfortunately, it 
became evident through routine follow-up that this improvement was short-lived in many 
CSII users, as evidenced by declines in HgA1c levels over time. This decline may be 
associated with a knowledge deficit, poor patient compliance with the use of this 
sophisticated technology, a lack of sufficient patient education focusing on CSII 
technology, or the interaction between the patient and health care provider.  
The objective of the evaluation of the QIP is to recognize the impact of three 45-
minute educational sessions on compliance and reduction in HgA1c. As the QIP has not 
been evaluated, there is a gap between administration of advanced education for PLWD 
using CSII therapy and the outcome of that education. Normalizing HgA1c levels in 
PLWD requiring insulin therapy promotes better patient outcomes, decreases morbidity 
and mortality rates, and improves socioeconomic consequences and quality of life. With 
the normalization of glycemic control, PLWD will experience a reduction in negative 
effects of diabetes such as nephropathy, neuropathy, and retinopathy, along with 
cardiovascular problems. 
In this section of the paper, the evidence-based model used to guide the QIP 
project is described in further detail, along with the project’s relevance to nursing 
practice, and the local background and context in which the project was developed. The 
role of the DNP study is further outlined in this section.  
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Frameworks, Concepts, and Models 
The use of theory in advanced practice nursing is necessary to provide a 
framework in directing patient care and implementation of interventions. The Integrated 
Theory of Health Behavior Change (ITHBC) is a framework that works to engage the 
patient in positive behavior changes to improve or manage chronic illness. Ryan (2009) 
found that approximately 50% of chronic illness is caused by personal behaviors. The 
promotion of health and behavior changes is critical in improved patient outcomes. The 
ITHBC theory was the framework used to guide the nurse-led educational sessions for 
the QIP as it fostered increased participant knowledge, understanding and self-
management skills when using CSII therapy (Ryan, 2009). As the ITHBC promotes 
engagement in self-management behaviors, the desired outcome is positive long-term 
change (Ryan, 2009). Ryan (2009) found that self-regulation, the key component of the 
ITHBC, recognizes the importance of setting appropriate goals, self-monitoring, which is 
a critical component to success of CSII therapy, decision making, and planning for, as 
well as engaging in, specific behaviors needed to adequately and safely control a chronic 
illness. The ITHBC also engages in social facilitation understanding the impact of social 
influence, support and promotion of self-management skills (Ryan, 2009). All the 
components of the ITHBC provided the needed guidance for a successful outcome of the 
QIP.   
The CDC Process Evaluation Model (PEM) is defined as a business process that 
has a specific order of activities that occur across time and place (CDC, 2004). This 
model is a structure that emphasizes six interlinked steps that provide the framework to 
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tailor an evaluation toward a specific goal that is time oriented. The CDC PEM helps to 
organize and summarize the important elements of the QIP. Each step in the evaluation 
process is reliant on the completion of the previous step, creating a focal point of 
completion to move forward (CDC, 2004). The CDC PEM is a representation of one or 
more processes and the association of these processes performed by the research team 
(CDC, 2004). Utilizing a model that describes activities across time and place helped to 
distinguish and define gaps in the QIP and optimized glycemic control. Future objectives 
will also be defined by the PEM, as it will recognize areas that need improvement for 
successful outcomes.  
Project Relevance to Nursing Practice 
Nursing can provide diabetic education, especially in the early stages of T2D, as 
illustrated by Robertson (2012). Robertson reports clinical studies that support the 
positive effects of patient education and self-management, leading to better clinical 
outcomes. Also, according to Robertson, with well-informed patients, prevention of 
chronic disease will be evidenced through normalization of HgA1c levels. This, in turn, 
will promote improvement in quality of life and decrease in health care costs. Education 
is key in promoting better outcomes with PLWD requiring insulin therapy and those that 
require CSII therapy.  
Diabetes affects 25.6 million Americans over the age of 20 (Robertson, 2012). 
Early diagnosis improves outcomes; however, the management and/or treatment of 
diabetes is paramount in the reduction of chronic disease. Nursing is pivotal in fostering 
patient/provider interaction along with introducing the necessary education and support 
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based on preventive treatment modalities along with lifestyle modifications. As nursing is 
patient oriented, spending more time with patients over physicians, the opportunity for 
education is more attainable. Robertson (2012) recognized the importance of behavioral 
patterns affecting lifestyle choices, along with continued patient/provider interaction; 
behavior and interaction are pivotal at enhancing the success of CSII therapy. Nursing 
has a solid role in reinforcing lifestyle changes with each encounter with a patient, 
reinforcing previous educational experiences. This doctoral project offers a better 
understanding in the gap between the use of CSII therapy, education, the normalization of 
glucose levels, and nursing’s role in the educational process. As indicated through the 
researched literature, CSII therapy promotes improved HgA1c levels. However, with the 
necessary education and nurse/patient interaction, outcomes may improve.  
Literature Review 
Search Strategy 
To find the most appropriate evidence-based literature associated with CSII 
therapy, self-care management skills, and education, multiple search sites were used. 
These include Medline, Cochran, ProQuest, PubMed, Cumulative Index to Nursing, 
Google Scholar and Allied Health Literature (CINAHL). All studies used included a full-
text search with peer-reviewed articles. Keywords such as diabetes, CSII, insulin pumps, 
MDI, usability, HgbA1c, type 1 diabetes, type 2 diabetes, and education were used in the 
search for relevant evidence-based literature. The initial search, which used keywords 
diabetes and education, elicited 2,709,276 articles. With the addition of the other 
important keywords, such as nursing and insulin pump therapy, articles were narrowed 
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down to 861,926, with a final narrowing of the search to 25,852. Upon review of the most 
relevant and up-to-date literature, 176 articles were accepted for a much more thorough 
review, of which 10 articles were used for the literature review based on the criteria set 
for the project. 
This literature review provided an overall understanding of CSII therapy, the 
technology associated with this state-of-the-art treatment, as well as diabetes education 
and the positive effects of these concepts in the optimization of HgA1c and glycemic 
control. This literature review also addressed the absence of research associated with 
T2D and the use of CSII therapy to optimize glycemic control, along with providing an 
improvement in overall quality of life for all PLWD. Health-related quality of life 
(HRLQ) is an essential element in the outcome of clinical trials, as well as overall health 
care (Varni et al., 2003). Diabetes Quality of Life (DQOL) measurement is the disease 
specific HRLQ used to pinpoint complications and recognize control of diabetes through 
educational measures, according to Varni et al. (2003). Despite new technology, 
therapeutic and treatment modalities, diabetes for most PLWD continues to be sub-
optimally controlled. This is where additional educational approaches that focus on both 
the technological aspect of CSII therapy, as well as a personalized approach to diabetes 
education, can enhance treatment plans and promote improvement in glycemic control.  
Nicolucci et al. (2013) found that most PLWD are not actively engaged with their 
health care providers and that education, along with psychosocial guidance, is missing in 
the treatment approach. In the Diabetes Attitudes, Wishes and Needs second study 
(DAWN2), 8596 adults with the diagnosis of diabetes in 17 countries were enrolled 
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(Nicolucci et al., 2013). Interestingly, as Nicolucci et al. (2013) found, no one country’s 
outcomes were better or worse than others. Depression, using the WHO-5 Well-Being 
Index [(WHO-5) score < 28] was 13.8%, diabetes-related distress [Problem Areas in 
Diabetes Scale 5 (PAID-5) score > 40] was reported by 44.6% of participants, and overall 
quality of life was rated either ‘poor’ or ‘very poor’ by 12.2% of participants (Nicolucci 
et al., 2013).  
Identifying personal barriers associated with diabetes is necessary in designing a 
personalized educational program for PLWD. This DNP student theorizes that, through 
the evaluation of the QIP, future nurse-led educational opportunities can be developed 
based off of the evaluation principles and outcomes. With a better understanding of the 
outcomes of this QIP through the evaluation, the promotion of future nurse-led 
educational opportunities can enhance positive patient outcomes in a multitude of chronic 
illnesses.  
Education is the basis of understanding any disease process, and relieving the fear 
associated with the unknown. Maia, Reis and Torres (2016) found that in a longitudinal 
descriptive study providing self-care management education to 151 adults living with 
T2D aged 30-85, participants gained improvement in self-management skills (P < 0.05). 
Wu et al. (2013) also conducted a Quasi-experimental design study analyzing the efficacy 
of improving diabetes disease management after implementing a self-management 
program with people living with T2D. The study consisted of two groups, an 
experimental group (n = 141) and a control group (n = 81) (Wu et al., 2013). Post test 
scores were collected for body mass index (BMI) (P <0.001), waistline circumference (P 
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< 0.01), HgA1c (P < 0.001) and depression/anxiety (P < 0.001) in the experimental 
group versus the control group. Post-test scores were colleceted for self-efficacy (P < 
0.001) for the experimental group versus control (Wu et al., 2013). Both studies 
demonstrate that PLWD can effectively improve self-efficacy/management with 
educational programs that highlight specific barriers associated with optimizing diabetes 
control.  
A significant problem associated with the use of CSII therapy is problem-solving 
when technology fails. This can become a major deterrent in the optimization of glycemic 
control. Fitzpatrick et al. (2013) demonstrated in a systematic review appraising sixteen 
intervention randomized controlled trials and eight quasi-experimental intervention 
studies, that 36% of the adult participants, along with 42% of children, displayed 
significant improvement in HgA1c. A systematic review performed by Wilkinson et al. 
(2014) focused on barriers/influences of self-management/self-care in adults with T1D 
and T2D. Interestingly, Wilkinson et al. (2014) found that there were barriers associated 
with the day-to-day management of diabetes including communication with providers 
and lack of educational programs providing the appropriate skills to successfully self-
manage diabetes. The provision of patient-specific education is vital in the success of 
self-managing diabetes. It is evident in the literature that ample educational tools are 
either not available, or the time to deliver quality education to PLWD is lost with the 
quantity of patients seen in a clinic setting daily.  
Much of the literature recognized that CSII therapy is superior to MDI therapy in 
reducing the amount of insulin used daily, the number of hypoglycemic episodes, and the 
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improvement in quality of life for PLWD. Unfortunately, most of the literature was 
geared toward T1D and the use of CSII therapy and very little was found regarding T2D. 
It is evident that, sooner than later, beta-cell production is restored with the use of insulin 
in the T2D population (Choi et al., 2013). Choi et al. (2013) found that, after 6 months of 
CSII therapy (P <0.001), HgA1c was decreased from 8.7% at baseline to 6.3%, and 
during the subsequent 24 months, median HgA1c levels were maintained between 6.3% 
and 6.5%. C. Peptide levels also began to improve after 12 months of CSII therapy (Choi 
et al., 2013).  Ghazanfar et al. (2016) studied that the use of CSII therapy improved the 
quality of life in PLWD, improved self-esteem and mood, and decreased stress and 
improved. Those participants in the study who were switched from MDI therapy to CSII 
therapy showed a significant decrease in insulin requirement (P <0.005) from 1.7 + 0.9 to 
1.1 + 0.6. This is a substantial finding, as weight gain will ensue with the increase of 
rapid insulin, especially in T2D (McCulloch, 2016.)  
Deeb et al. (2015) studied the association of various key elements of CSII 
technology and the functionality of insulin pump therapy and the effects on blood glucose 
levels. Deeb et al. (2015) found that the frequency of blood glucose control monitoring, 
and the use of the Bolus Wizard feature of CSII therapy/technology, had favorable 
association with glycemic control. Upon review of the QIP, this DNP student theorizes 
that, with the provision of basic and advanced CSII technological training, along with 
patient-specific diabetes educational training, specifically self-management skills, 
improvement in glycemic control will ensue. When CSII therapy is initiated, training 
includes the insulin pump start with a diabetic educator from the desired insulin pump 
28 
 
manufacturer/company, which takes a couple of hours. Dependent on the clinic setting 
initiating the CSII therapy, training can include the initial start date, or can be extended 
out for a couple of days. This is not sufficient in providing the skills to appropriately 
apply the technology and sufficiently improve glycemic control. This was evidenced by a 
number of PLWD utilizing CSII therapy that were not controlled in the current setting of 
the diabetic clinic. This information then prompted the clinic to design a QIP that focused 
on nurse-led education and CSII therapy.  As the DNP student works as a full-time nurse 
practitioner in this clinic setting, it was the desire of the student to then close the gap in 
the QIP, which was the evaluation phase to identify the outcome of the QIP educational 
sessions.   
Reznik et al. (2014) conducted the largest study thus far for T2D utilizing CSII 
therapy, with 331 adult participants. This was a randomized control trial, with 168 
participants started on CSII therapy and 163 on MDI therapy (Reznik et al., 2014). 
Baseline HgA1c was 9% for both groups, with the study being conducted over a six-
month period (Reznik et al., 2014). Reznik et al. (2014) found that the CSII group 
reduced HgA1c by 1.1% in comparison with a 0.4% reduction in the MDI group. This 
study provided statistical data favoring CSII therapy use in the T2D population and the 
reduction and optimization of HgA1c and glycemic control. Again, a meta-analysis 
conducted by Weissberg-Benchell (2003), consisting of both adults and children with 
T1D, found that CSII therapy improved glycemic control better than when compared to 
MDI therapy. Finally, Li et al. (2016) conducted a randomized, parallel study comparing 
three groups of T2D participants using CSII therapy versus MDI therapy that consisted of 
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3 MDI and 4 MDI. Findings were consistent, with CSII experiencing the most 
improvement in glycemic control over MDI therapy (4.26 + 1.88 days) in the CSII group 
versus (6.17 + 2.36 days) MDI3 group, and (5.81 + 2.46) in the MDI4 group; CSII group 
(P < 0.05) versus MDI3 and MDI groups (Li, et al., 2016). Li et al (2016) also found that 
the longstanding T2D group fared better on CSII therapy versus MDI3/4 therapy (P < 
0.05).  
Interestingly, although these studies provided insight into the problems associated 
with self-management and diabetes, along with the lack of studies in regard to T2D and 
CSII therapy, there is a barrier associated with the optimization of glycemic control and 
the utilization of CSII therapy in PLWD, both T1D and T2D. This is why further study is 
needed to discover whether the technological advancements of CSII therapy prevent 
PLWD from optimally controlling their HgA1c. 
Evidence to Address the Gaps-in-Practice  
Reviewing the literature, the gaps-in-practice regarding CSII therapy were mixed, 
as there were positive and negative outcomes associated with the initiation and continued 
use of CSII therapy. Some of the studies had a limited time exposure to the treatment, 
which could identify the positive outcomes; however, few of the studies focused on the 
nurse-led educational segment that is associated with this DNP project. Gaps-in-practice 
with education were very similar to what the diabetic clinic is identifying with many of 
the PLWD using CSII therapy. Unfortunately, the literature was focused mainly on self-
management education and not strictly on person-specific education, focusing on both the 
promotion of self-management skills and technological training for CSII use. For these 
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reasons, it is very important to promote diabetic education that encompasses not only the 
promotion of self-management but is also geared toward the ever-changing technological 
aspect of medicine. A summary of this project’s literature view is presented in Appendix 
B.  
Local Background and Context 
Evidence to Justify the Problem 
Advances in the monitoring and controlling of HgA1c in PLWD requiring insulin 
therapy has improved with new technology, specifically CSII therapy. With review of 
existing PLWD insulin pump downloads (Trend reports) at the diabetic clinic, it has 
become evident that there is a gap in the use of CSII therapy and normalization of 
HgA1c. Even with the convenience associated with using CSII therapy, patient 
compliance, knowledge deficit, or patient/provider interaction may be barriers to 
normalization of HgA1c levels. 
There is variable success with the CSII therapy reported in the literature as well 
(Li, et al., 2016). The initiation of CSII therapy results in a rapid HgA1c reduction, but 
then it begins to increase within the first year of therapy. The objective of this DNP 
project is to evaluate the impact of the QIP on knowledge deficits and HgA1c levels. It is 
theorized that the elevation in HgA1c after initiation of therapy is related to the basic 
education provided at the start of therapy, along with only routine quarterly follow-up 
visits for insulin pump adjustments, many times made by the provider (Maia, 2016). 
Upon evaluation of the QIP, we hope to identify whether there is a gap in nursing and 
patient education preventing positive outcomes associated with CSII therapy. 
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Institutional Context 
The intended practice setting is a diabetic clinic located in large southwestern 
state that sees an estimated 100 adult patients daily for a number of endocrine disorders. 
Approximately 50 percent of these patients have diabetes. There is a large volume of 
diabetic patients that require oral glycemic agents, as well as MDI and CSII therapy. The 
DNP student’s affiliation with the practice is as a full-time practicing family nurse 
practitioner working closely with diabetic patients.  
Definition of Relevant Terms 
Basal insulin: A continuous 24-hour delivery of insulin mimicking the function of 
the pancreas (Walsh & Roberts, 2013). 
Blood glucose level:  Measurement of serum blood glucose levels (Walsh & 
Roberts, 2013). 
Carbohydrate counting: The carbohydrates in any given food (Walsh & Roberts, 
2013). 
Continuous subcutaneous insulin infusion (CSII): Insulin pump therapy (Conget 
et al., 2016). 
Correction bolus: A delivery of insulin to correct a high blood glucose levels 
(Walsh & Roberts, 2013).  
Diabetic neuropathy: Damage to nerves  resulting from poor glycemic control 
(Walsh & Roberts, 2013).  
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Diabetic retinopathy: Visual problems created from damage to the small vessels 
in the eyes, which can cause blindness resulting from poor glycemic control (Walsh & 
Roberts, 2013).  
Glycated Hemoglobin (HgA1c): Is the most widely used clinical test correlated 
with diabetes; HgA1c is the estimation of blood glucose control as red blood cells are 
highly permeable to glucose (McCulloch, 2016). HgA1c reflects a mean blood glucose 
over a period of 8 to 12 weeks (McCulloch, 2016). 
Hypoglycemia: Lower than normal blood glucose levels defined as blood glucose 
levels <70 (Walsh, Roberts, 2013).  
Hyperglycemia: Higher than usual blood glucose levels defined as blood glucose 
levels >100 (Walsh & Roberts, 2013).  
Insulin Pump: A small device that is programmed to delivery basal/bolus insulin, 
replacing MDI therapy (Walsh & Roberts, 2013). 
Multiple Daily Injections (MDI): Insulin delivery via multiple daily subcutaneous 
injections (Conget et al., 2016). 
Type 1 diabetes (T1D): Destruction of pancreatic beta cells, which then leads 
complete insulin deficiency is the classic characteristic of T1DM (McCulloch, 2016). 
Type 2 diabetes (T2D): Hyperglycemia, insulin deficiency and resistance are the 
classic characterizations (McCulloch, 2016); the most common type of diabetes. 
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Role of the DNP Student 
Professional Relationship to the Project 
At Walden University, the DNP student is prepared through scholastic and 
clinical experiences to meet the foundational elements outlined by the American 
Association of Colleges of Nursing (AACN). The Doctor of Nursing Practice Program 
(DNP) at Walden University promotes the student’s understanding of what roles and 
responsibilities they should possess upon graduation. Through this preparation, my final 
requirement of this DNP program was to evaluate an EB-QIP project at my chosen 
practice setting prior to graduation (Walden University, n.d.). This project fulfills all 
criteria to formally graduate as a knowledgeable DNP and further the future of nursing 
through continued EB-QIPs.   
Professional Role in the Project 
Currently, my professional role is working as a family nurse practitioner (FNP) in 
the diabetic clinic setting that is my chosen practice setting. My role in this setting for 
this project is also as the DNP student, working daily with PLWD who require both oral 
antiglycemic agents, MDI, and CSII therapy. With my current position as an FNP, I am 
uniquely qualified to identify the shortfalls in glycemic control with oral antiglycemic 
agents, as well as MDI and CSII therapy, as I work daily with PLWD and formulate 
treatment plans.  
Participants in the QIP included patients at the clinic who had been initiated on 
CSII therapy. All information was provided by the diabetic clinic and was not be 
retrieved by the student. No patient identifiers were used in the evaluation process, as all 
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data was categorized by groups i.e., male/female. Upon categorizing the data, I was able 
to recognize trends in adherence to therapy, technological difficulties, and the effects of 
lifestyle on diabetes.  
Motivations for the Doctoral Project 
Working daily with PLWD requiring CSII therapy, the DNP student recognized a 
trend between the initiation and follow-up of CSII therapy, and a gap in normalizing 
glycemic control. It has been the DNP student’s experience, through close observation 
and working with PLWD requiring insulin therapy, that initially there is significant 
improvement in HgA1c levels within a six-month period from initiation of CSII therapy; 
however, this improvement is not sustained. There may be a number of factors that 
preclude the sustainment or normalization of glycemic control. These include, but are not 
limited to, patient tolerance and/or intolerance to insulin and therapy; biological changes 
to the patient as a result of age or gender; endocrine system function; patient lifestyle and 
stress levels; provider interaction and/or monitoring intervals; Sensory-Augmented Pump 
Therapy (SAPT); and CSII technological shortfalls (Maia, 2016). It is the goal of this 
project to identify whether this trend is the norm, or a lack of sufficient education in both 
self-management skills and technological training specific to CSII therapy.  
Potential Bias 
The appearance of bias may be implied if the evaluator of a QIP favors a 
particular outcome. This could potentially cause bias toward the outcome of the 
evaluation, having it lean closer to the favored end. Another form of bias could be the 
selection of the participants in the QIP. As the QIP involved nurse-led educational 
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sessions, participants with high learning aptitudes could have been chosen, which could 
have promoted a favored outcome as well. As the DNP student did not chose the 
participants in the QIP, and will not be extracting data for the evaluation process, bias 
should not be an issue. Upon initiation of the QIP, the diabetic clinicians felt it was best 
to use one manufacturer for the initial training. As there are three main CSII 
manufacturers that the diabetic clinic works with, using one manufacturer eliminated any 
bias upon evaluation of the QIP, as each manufacturer has different reports to follow 
behavior, blood glucose levels, and administration of insulin. The use of one 
manufacturer allows for equal evaluation of the trend report categories. 
Summary 
There is variable success with CSII therapy reported in the literature. HgA1c is 
the gold-standard measurement of glycemic control, and affords health care providers a 
value in which to recognize a patient who may be noncompliant, complacent, or lacks the 
knowledge associated with optimizing CSII technology. It has been identified that 
patient-provider interaction is critical to the success of lowering HgA1c levels and 
optimizing the use of CSII technology. Nursing plays a pivotal role in delivering specific 
patient-centered education/training on CSII technology and self-management of diabetes, 
as evidenced by the literature.  
Patient behavior impacts the longevity of CSII therapy, and can be transformed 
with appropriate educational approaches within the nursing context. As evidenced in the 
literature thus far, optimization of CSII therapy is questionable, which can be attributed 
to a number of reasons. This DNP project will evaluate the success of the QIP, which 
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consisted of three 45-minute educational sessions and their impact on improvement in 
HgA1c and patient compliance. It is theorized that, with the proper tools through 
continued education to operate CSII technology, PLWD will become more compliant in 
entering the correct data, in turn receiving the appropriate amount of insulin to optimize 
glucose levels and improve HgA1c levels.  
Essential for the implementation and evaluation of any intervention employed by 
advanced practice nurses is to identify theories specific to the intervention and evaluation 
desired. The ITHBC theory was used as the framework of the QIP, along with the CDC 
PEM theory that was used in this DNP project as the framework to guide the evaluation 
of the QIP. By using a theory-based approach in nursing, time wasted in evaluating 
irrelevant material and the avoidance of distractions can be prevented. Also, use of a 
theoretical framework can foster improvement in communication among peers, patients, 
and other professionals.  Using the CDC PEM and the ITHBC Theory, recognition of 
possible shortfalls in the educational process can be ascertained and adjustments to the 
educational program can be applied to improve health outcomes of future participants.  
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Section 3: Collection and Analysis of Evidence 
Introduction 
Quarterly follow-up visits for PLWD using CSII therapy have been routine at the 
diabetic clinic where the QIP took place. These routine visits include insulin pump 
downloads and interpretation of the data retrieved from the Adherence Report, among 
other reports. This interpretation helps the clinician determine any necessary changes to 
help optimize glycemic control. In depth education focusing on CSII technology is 
minimal at these visits for a number of reasons, most significantly time restraints. This 
has resulted in many PLWD underusing the many functions of the CSII technology. The 
purpose of this DNP project was to evaluate the impact the QIP had on promoting self-
management skills and improving the knowledge deficit and HgA1c levels.   
As identified in the literature review, Bode (2010) found that the complexity of 
CSII technology was a notable barrier to the compliance of PLWD, as well as 
optimization of HgA1c levels. Bergenstal et al. (2013) found key contributors to poor 
glycemic control among PLWD utilizing CSII therapy included the underutilization of 
glucose data, as well as inconsistent glucose data collection. This is a common 
occurrence in the diabetic clinic and prompted this DNP project.  
This section elaborates on the study design, extraction of data, methodology and 
description of how the extracted data was analyzed. Specific goals and objectives are 
established in order to develop an appropriate research methodology to secure a positive 
endpoint in successfully reaching the goals and objectives identified for this DNP project. 
Upon completion of the evaluation of the QIP initiated at the diabetic clinic, recognition 
38 
 
of possible short-falls in the educational program can be identified and corrected to 
improve outcomes for future program participants.   
Practice-Focused Question 
Thanks to new technology, there have been significant advances in the monitoring 
and controlling of HgA1c in PLWD over the last decade. Despite these advances, PLWD 
requiring insulin using the most up-to-date technology, for example CSII therapy, 
continue to fall short in optimizing HgA1c levels. Working closely with the diabetic 
population in the diabetic clinic setting, through evaluation of data derived from the 
insulin pump Adherence/Trend Reports, I discovered that there is an apparent knowledge 
deficit in the correct use of the technology. This deficit, or problem, became the focus of 
the DNP question: How will nurse-led educational sessions for PLWD using CSII 
therapy impact the knowledge deficit and HgA1c levels? As Wu et al. (2013) 
demonstrate, continued patient education can improve self-efficacy and self-management 
of diabetes, promoting awareness of the importance of diligent glucose monitoring and 
proper use of advanced technology. Without the tools to be successful in these advanced 
technologies, many PLWD will be at a loss in managing the intricate applications of 
CSII.  
Project Purpose and Method Alignment 
The purpose of the DNP project was to evaluate the QIP that was implemented at 
the diabetic clinic that consisted of three 45-minute educational session for PLWD using 
CSII therapy. The data retrieved for the evaluation process was provided to me from the 
clinic for evaluation purposes, allowing me to recognize trends in adherence to therapy, 
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technological difficulties, and the effects of lifestyle and diabetes. No patient identifiers 
were used in the evaluation process, as all data was placed in categories appropriate for 
the evaluation. Also, through the evaluation, the data retrieved via the Trend reports 
distinguished whether or not there was improvement in compliance, understanding and 
usability of CSII therapy. This information is relevant, as attitudes of PLWD play a 
significant role in compliance and optimized HgA1c levels. Evaluation of all data, 
combined through Trend reports and aggregate serum laboratory HgA1c levels 3 months 
pre-education and 3 months post-education, served as a means of quantifying the end 
goal of this QIP: improved compliance and HgA1c levels.  
Key Operational Definitions 
Adherence Report: Reports patient behavior data for a specific period of time 
(normally 2 weeks). This report provides adherence through data such as glucose 
measurements, bolus events, and insulin pump activities (Medtronic, 2009).  
Log Book Report: Presents glucose, carbohydrate levels, and insulin infused on 
hourly intervals (24 hours). This report recognizes glycemic control over a specific 
period of time (2 weeks) (Medtronic, 2009). 
Device Settings Report: This report lists all insulin pump settings. This 
information is used as a guide in the interpretation of other reports and to make 
appropriate adjustments to insulin distribution based off of information obtained through 
the other trend reports (Medtronic, 2009). 
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Trend Reports: A few reports that include all function of CSII technology 
focusing on usage by the user. These reports are used to properly monitor and adjust 
treatment (Medtronic, 2009). 
Statistics Table: Provides measurements including average blood glucose, number 
of meter glucose reading, readings above and below target settings, carbohydrate daily 
average, bolus daily average, basal daily average, and average total daily insulin 
(Medtronic, 2009).  
Sources of Evidence 
Archival and Operational Data 
 The clinic used two sources of data, current and archived. Data used for this 
evaluation came from the electronic medical record (EMR), as well as the CSII database. 
All information was provided to me by the diabetic clinic for evaluation purposes. No 
patient identifiers were used in the evaluation process.  
Description of Data Collection 
The diabetic clinic provided all data necessary for the evaluation void of patient 
identifiers. Data consisted of information provided from each participant’s Medtronic 
insulin pump Trend Reports, specifically the Adherence Report. The extraction of 
Adherence Reports occurred at each visit at the diabetic clinic and was recorded in the 
patient’s electronic record. The Adherence Report focuses on behavioral data that is 
based off of daily indices such as glucose measurements, bolus events, and other insulin 
pump activities (Medtronic, 2009). Aggregate serum HgA1c levels were provided to me 
from the diabetic clinic at 3 months pre-education and 3 months post-education and, 
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again, no patient identifiers were present as each data set was placed into categories for 
evaluation. 
Participants 
 This EB-QIP took place at the diabetic clinic where I work as a full-time FNP, 
and am completing my clinical experience as a student. The participants of the EB-QIP 
were male and female patients at the diabetic clinic who volunteered to participate, were 
> 18 years of age, with T1D and T2D using a CSII device (Medtronic) for glycemic 
control with a HgA1c > 8. 
Procedure   
 Walden University requires that an Institutional Review Board (IRB) application 
be completed by all DNP students for EB-QIP projects that include the collection and 
analysis of data concerning people, projects that are addressing gaps in practice, and all 
doctoral projects (Walden University, n.d.). The IRB approval ensures proper conduct 
from the DNP student in performing the EB-QIP, along with the evaluation of the EB-
QIP devoid of any coercions to the participants of the EB-QIP (Walden University, n.d.).  
As stated earlier, all data was retrieved from the diabetic clinic, void of patient 
identifiers, and provided to me for evaluation of the QIP. This commenced only once IRB 
had been approved. With the use of the categorical data, along with aggregate serum 
HgA1c levels pre-and post-educational sessions that were also categorized between male 
and female participants, trends were identified indicating success or need for educational 
session improvement.   
Protections 
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Pump reliability and validity was based on approval through the Federal Food, 
Drug, and Cosmetic Act (FDA). This Act includes annual registration, listing of devices, 
good manufacturing practice, labeling, and prohibitions against misbranding and 
adulteration. Safety assurance cases are provided to the FDA for pump devices, which 
demonstrate acceptability of risk mitigations, adequate device reliability, and adequate 
designs verification and validation of device specifications (HHS, 2015). Patient 
reliability was not guaranteed as necessary data to create sufficient information for pump 
download needed to be uploaded into the device by the patient.  
Analysis and Synthesis 
Data Systems and Procedures 
 Microsoft Excel was used to organize data, data sets, and variables. Maintaining 
control of the data collection, specific criteria must have been met prior to entering a 
participants’ information into the project; as I was not retrieving the information, and was 
provided it from the diabetic clinic performing the QIP, all data was required to be void 
of any patient identifiers. Also, all data was placed in categories specific to the evaluation 
process. This information was vital to the findings and outcomes of the project.  
Data Integrity 
 If there was any data missing from the CSII downloads, it was first determined if 
this information had a significant impact on the analysis. As Grove et al. (2013) explain, 
it may have to be excluded from the project depending on the impact of the information. 
During the evaluation of the EB-QIP, outliers may have been identified. According to 
Polit (2010) outliers are numerical values that are outside the normal range of the values 
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for the other data. An example of an outlier for this project would include those 
participants with glycemic control that appeared to be optimized by a serum HgA1c level 
well below 6.0. However, false appearing-optimized HgA1c could have been in relation 
to blood glucose variability, which can cause untoward effects on internal organs.  
Significant variability in blood glucose levels can be as hazardous to the 
promotion of complications from diabetes as uncontrolled hyperglycemia is (Service, 
2013). This variability is also a sign of knowledge deficit in the understanding/usability 
of CSII technology. To ascertain the accuracy of an outlier, the data needed to be 
scrutinized to identify where the error occurred. Errors could have occured while data 
was entered either by using improper values or codes as Polit (2010) explains. Also, Polit 
(2010) reports that outliers can be found through data cleaning; inspecting values through 
the frequency distribution.  
Data Analysis 
A simple t-test was used to compare two averages and identify differences, and as 
to whether those differences happened by chance. Also, a run chart was used to review 
the trends for each CSII download look at the progression of specific data points over 
time. The run chart was important, as non-statistically significant trends can be identified 
with multiple data points over time. 
Descriptive statistics were used to summarize the sample characteristics and from 
this description a frequency variable was plotted based off specific variables such as 
HgA1c levels, number of times patients checked their blood glucose levels daily, number 
of times the tubing/setting was changed, and number of times BWZ and the override 
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function were used. IBM SPSS software was used for the statistical analysis of this 
project.  
Summary 
 Medications and technology have had a profound effect on diabetes; however, 
with even the newest advances in technology, normalization of HgA1c with the use of 
CSII therapy still has its downfalls. Through evaluation of quantitative data retrieved 
from serum laboratory studies and data from the Trend Reports acquired from the CSII 
database, recognition of the gap in achieving improved glycemic control, as well as self-
management skills for those PLWD utilizing CSII therapy can be achieved.  
With the implementation of the three 45-minute educational sessions, and the 
existing data gathered pre- and post-session, the evaluation of the EB-QIP identified gaps 
in education, the use of CSII therapy, and the optimization of glycemic control. The 
population size was determined based on the criteria established by the diabetic clinic 
performing the QIP. All ethical principles were followed closely during the evaluation of 
the QIP in order to protect participant information. No personal information was used or 
divulged in the study.  
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Section 4: Findings and Recommendations 
Introduction 
Regardless of being given the most up-to-date treatment for T1 and T2D, using 
the most advanced technology in the form of CSII therapy, PLWD continue to struggle 
with controlling blood glucose levels. Complications associated with uncontrolled 
diabetes include, but are not limited to, cardiovascular/cerebrovascular disease, renal 
impairment, vision problems such as retinopathy, and peripheral neuropathy that can lead 
to amputations (McCulloch, 2016). McCulloch (2016) estimates that 14% of health care 
expenditures in the United States, or $245 billion, is used to treat the complications 
associated with uncontrolled diabetes. 
 Type 2 diabetes is on a swing upward in growth, with expectations of an increase 
to approximately 64% according to Rowley and Bezold (2012). This is an increase from 
19.1 to 53.1 million by the year 2025 (Rowley & Bezold, 2012). That new treatment 
modalities such as oral glycemic agents, improved insulin dialogs, and updated 
technology do not appear to be controlling the issue at hand is concerning. T2D is 
expected to increase to approximately 415 million cases worldwide (Rowley & Bezold, 
2012); equating to an annual economic impact of $500 billion.  
 Through my observation of PLWD utilizing CSII therapy in the clinic setting, it 
had become obvious that there was a gap between the initiation of CSII therapy in PLWD 
and continued education. This gap may contribute to the lack in achievement of optimal 
glycemic control. Through evaluation of insulin pump reports it was also apparent that 
that many CSII users were making use of only minimal features of the CSII technology. 
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As a result, the development of a quality improvement project was initiated to determine 
whether a nurse-led educational program would enhance the usability of the CSII 
technology, thus improving HgA1c levels and outcomes by reducing complications 
associated with T2D. The primary concentration of the practice-focused question was 
whether a nurse-led educational program could promote self-management skills, improve 
the knowledge deficit with regard to the usability of CSII technology in PLWD, and 
improve HgA1c levels. With the practice-focused question aligned, three 45-minute 
nurse-led educational sessions were performed specific to each participant. The purpose 
of this doctoral project was to evaluate the outcome of the educational sessions and to 
determine whether there was a positive impact on the participants’ HgA1c levels post-
education.  
 I obtained evidence for this project through the insulin pump reports downloaded 
with each session, using the Adherence Report, and the serum aggregate HgA1c levels of 
each participant three months pre-education and post-education. The Adherence Report 
provides information about the participant’s compliance with the use of CSII technology, 
allowing for daily, weekly and monthly views of usability. Serum aggregate HgA1c 
levels are important in gauging improvement in participants’ glycemic control. 
Subsequently, I categorized and assessed the information obtained to determine 
participants’ improvement in CSII features. I assessed serum aggregate HgA1c levels to 
recognize improvement and/or failure to improve from the initiation of the program. Prior 
to the implementation of the project, I obtained an approval from the internal medicine 
47 
 
clinic’s director, as well as Walden Universities Institutional Review Board (IRB); IRB 
approval number is 01-30-18-0410353 . 
Findings and Implications 
Demographics and Descriptive Data 
 Over a period of six months, a total of 122 patients were identified as potential 
participants at the diabetic clinic where the QIP was performed. Out of the 122 patients, 
34 signed up to participate in the QIP, a nurse-led educational program that consisted of a 
series of three 45-minute educational sessions that were patient-specific. One nurse 
practitioner at the site performed the educational sessions and reviewed the Adherence 
Reports, most specifically the Trend Reports and serum aggregate HgA1c levels. This 
information created the guiding principles of the QIP.  
Out of the 34 participants, one expired, three were lost to follow-up, and four 
withdrew from the program due to time restraints. PLWD (T1D and T2D) who utilized 
CSII therapy for the administration of insulin for one year or greater were included in the 
QIP. Other parameters for inclusion in the program were participants having a HgA1c > 7 
or significant variability in daily blood glucose levels that can falsely lower HgA1c levels 
within optimum range. As Hirsch (2015) found, using the HgA1c to correlate diabetes 
control is leaving many people, especially those with T2D, with uncontrolled diabetes in 
relation to glycemic variability (GV), thus creating opportunity for continued 
complications associated with diabetes. According to Hirsch (2015), GV should be 
considered as a first-line indicator of optimal diabetes control.  
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Upon evaluation of the QIP, patient safety and privacy were of the utmost 
importance. There was no identifying participant information provided to me for 
evaluation purposes. All data collected was provided to me by the site that the QIP was 
performed. I placed the data in categories using Microsoft Excel. My analysis of the 
categorical information commenced upon IRB approval.  
Descriptive Data 
 The results of the evaluation involved secondary data consisting of Trend Reports 
from the insulin pumps, void of any participant identifying information, along with 
aggregate HgA1c levels provided by the site where the QIP took place. I placed all data 
into categories specific to the evaluation to provide a comparison from the initiation of 
education to completion of the educational program. The QIP consisted of 26 
participants; n=12 (46%) were male, and n=14 (54%) were female. Average age of the 
male group was 69.8 years; average age of the female group was 54.2 years, with an 
overall combined average age of 61.5 years.  
No oral glycemic agents or additional diabetic medications were added or 
removed from the participants’ regimen during the QIP, negating any additional 
adjustments to HgA1c levels r/t new medications or changes to current treatment 
regimen. This was done to avoid changing any of the end results that would alter the 
outcome of the educational program. All participants used one CSII manufacturer, 
eliminating any differences in technology, use, or performance. Aggregate serum HgA1c 
levels of each participant were provided to me for evaluation purposes, again, void of any 
participant identifying information.  
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Results  
 I performed all statistical analyses using IBM SPSS version 24, with all 
categorical information input into Microsoft Excel. I met the goal of determining the 
effect of the nurse-led educational sessions over time by performing a one-tailed, paired 
samples t-test with the level of significance set at .05.  I identified four categories 
allowing for the necessary statistical evaluation: serum aggregate HgA1c levels, blood 
glucose log use, Bolus Wizard use, and override use.  
Table 1 illustrates the comparison of the pre-education and post-education 
categories. Table 2 illustrates each category’s data. 
Table 1  
Comparison of Pre-Education and Post-Education Categories 
Variable Mean Standard Deviation P Value 
    
Pre-Education HgA1c 8.98 1.68 - 
Post-Education HgA1c 7.99 1.16 .001 
 
Pre-Education Bolus Wizard  3.67 2.26 - 
Post-Education Bolus Wizard 3.86 2.17 .246 
 
Pre-Education Blood Glucose 3.49 1.20 - 
Post-Education Blood Glucose 4.02 1.83 .081 
 
Pre-Education Override 
 
Post-Education Override 
14.26 
10.35 
24.68 
21.35 
    - 
.17 
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Table 2  
Trend Report Data Participants (n=26) 
Category Session 1 Session 2 Session 3 
 Average use Blood 
Glucose log 
  
Male/Female (n=26) 3.5 3.6 4.0 
Males (n=12) 3.9 3.9 4.3 
Females (n=14) 3.1 3.2 3.8 
 Average Bolus Wizard 
Use 
  
Male/Female (n=26) 3.6 3.8 3.8 
Males (n=12) 3.5 3.8 3.8 
Females (n=14) 3.8 3.7 3.9 
 Average Override %   
Male/Female (n=26) 14.3 14.2 10.3 
Males (n=12) 13.0 12.7 12.4 
Females (n=14) 15.3 15.4 8.5 
 
The above tables represent the four categories pre-education and post-education. 
The pre-education mean of serum aggregate HgA1c levels was M = 8.98 (SD = 1.68). By 
comparison, the mean of post-education serum aggregate HgA1c levels decreased to M = 
7.99 (SD = 1.66), t(25) = 3.8,  p< .05. 
 The mean of blood glucose log use, category two, was M = 3.49 (SD = 1.20) pre-
education. By comparison, post-education was associated with a numerically greater 
blood glucose log use, M = 4.02 (SD = 1.83), t(25) = -1.4,  p> .05. 
The mean of Bolus Wizard use, category three, was M = 3.67 (SD = 2.26) pre-
education. By comparison, post-education was associated with a numerically larger Bolus 
Wizard use, M = 3.86 (SD = 2.17), t(25) = -70, p> .05. 
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 The mean of override use, category four, was M = 14.26 (SD = 24.68) pre-
education. By comparison, post-education was associated with a numerically smaller use 
of the override function, M = 10.35 (SD = 21.35), t(25) = 2.4, p < .05. 
 
 
Figure 1. Blood Glucose Log 
 
Figure 2. Serum Aggregate HgA1c Pre/Post QIP 
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Figure 3. Average use of Bolus Wizard 
 
Figure 4. Average Use of Override 
The above figures demonstrate the comparison between pre-education and post-
education in the use of the blood glucose function, serum aggregate HgA1c levels, Bolus 
Wizard, and the use of the override function.  
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Unanticipated Limitations/Outcomes and Their Potential Impact on Findings 
 This project had a number of unanticipated limitations. First, the number of 
participants could have been larger to provide more data sets. With the small number of 
participants in the QIP, statistical significance in the analysis of the evaluation may have 
been lower than anticipated. Secondly, the turnover in medical assistant staffing within 
the diabetic clinic, and the need to train new staff, created issues with lost data from the 
insulin pump downloads, decreasing the potential for larger numbers of participants in 
the program. Vital information that is routinely extracted from each CSII device is to be 
scanned in each patient’s chart at each visit. With new staff, routine processes within the 
clinic were neglected and vital information was lost.  
 As insulin pumps are the newest technology in diabetes management, 
technological failures were also problems associated with the analysis of the programs’ 
success. There were a few participants who experienced technological difficulties with 
the insulin pumps requiring assistance from the manufacturer. In relation to lost data, two 
of the participants’ follow-up sessions had to be rescheduled to allow for appropriate data 
collection prior to the upcoming session. Expanding the hours of operation may have 
alleviated time-restraint issues that necessitated some participants withdraw from the 
program.  
Implications for Individuals, Communities, Institutions, and Systems 
 The implications of this study shed light on the importance of continued nurse-led 
education. Although the number of participants in the QIP was small, the results 
indicated improvement in all four categories with respect to number of times the 
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participants checked their blood glucose levels daily, the number of times the participants 
used the Bolus Wizard feature, and the reduction in the percentage of overrides 
performed by the participants. This information is critical in promoting improvement in 
blood glucose levels. The most telling statistic from the analysis of the data was the 
reduction in the overall HgA1c by an average of 1.1 post-education. This reduction in 
HgA1c is significant as indicated in the UKPDS study that demonstrated tight control of 
HgA1c levels proved decrease microvascular complications (King, Peacock & Donnelly, 
1999). 
 The results of this project have provided keen insight as to the importance of 
continued diabetic education in the prevention of the complications associated with 
uncontrolled diabetes at this clinic. As the future of diabetes treatment continues to 
rapidly change, it is crucial that providers, as well as patients, continue to be educated on 
the state-of-the-art technological changes used for the treatment of diabetes. 
 The diabetic clinic where the QIP and evaluation was performed is a very busy 
clinic, with approximately 50% of the patient population treated for diabetes. The average 
time allotted for patient visits is 15 or 30 minutes. This does not leave a great deal of time 
for patient education. However, upon my review of the results from the evaluation of the 
QIP, it has become apparent that with specific time set aside for more thorough 
education, improvement in HgA1c levels can be achieved. Though the diabetic clinic is 
independent, having no association with a hospital system or additional clinics, the 
findings can still be shared amongst nursing peers, prompting similar clinics to institute 
nurse-led education focusing on diabetes and the use of advanced technologies.   
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Legal, Ethical and Economic Implications 
 Beneficence, the act of preventing harm, is critical in the treatment of diabetes or 
any other chronic disease state. With the provision of educational sessions for PLWD 
utilizing CSII therapy, a better understanding of the importance of using this technology 
appropriately to arrive at the best end result is achieved. With the adoption of nurse-led 
educational sessions that focus on the use of the advanced technology associated with 
CSII therapy, along with continued promotion of self-management skills, complications 
associated with uncontrolled diabetes can be prevented. 
Diabetes has become a worldwide epidemic leading to chronic health conditions 
and crippling the financial welfare of the United States and many other countries through 
the world (McCulloch & Robertson, 2016). Screening for diabetes should be performed 
on all adult patients in order to identify the signs of prediabetes and provide adequate 
preventive treatment to reduce the complications associated with diabetes. PLWD who 
utilize CSII therapy need appropriate education focusing on the use of this advanced 
technology to optimally control HgA1c levels (Ghazanfar et al., 2016). This is an ethical 
dilemma in the medical community, as we are neglecting the ethical principal of ‘justice’ 
if we do not provide this life-saving education.    
It is the responsibility of the entire medical community to continue developing 
quality improvement projects to redesign and establish protocols and provide the best 
evidence-based practice principles (Fitzpatrick et al., 2013). Legally, it is our 
responsibility to continue to update and improve old standards of operation and 
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implement, through research, new standards of care to promote the best possible 
outcomes.  
Implications for Positive Social Change 
There are social implications associated with this project in a number of areas: 
PLWD, family members, the diabetic clinic, and the nursing profession. The results of 
this QIP have changed the process in which PLWD utilizing CSII therapy are educated in 
the diabetic clinic. PLWD who use CSII therapy will be provided additional time for 
short educational sessions with each office visit. The director of the diabetic clinic 
supported the QIP and has worked closely with the nurse practitioners in this clinic to 
establish new policies and protocols for patient education.  
Recommendations 
 The evaluation of the nurse-led education QIP program implemented in the 
diabetes clinic addressed gaps in knowledge deficits experienced by PLWD using CSII 
therapy for the treatment of diabetes. Formulating educational sessions that were 
participant-specific, and focusing on CSII technology and self-management skills, 
allowed a self-paced learning experience. The four categories that were the focus of the 
evaluation all demonstrated improvements post-education. At the start of the QIP, the 
average HgA1c level for the participant group was 8.98%; three months after completion 
of the QIP, the average HgA1c level for the participant group decreased to 7.99%.  
 The number of times blood glucose levels are checked throughout the day can 
positively influence a reduction in HgA1c over time. Looking at the blood glucose log, 
the average number of times the participants of the QIP checked their blood glucose 
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levels prior to the initiation of the QIP was 3.5 times daily. Three months post-
completion of the QIP, the average number of times the participants checked their blood 
glucose levels increased to 4.0 times daily.  
The Bolus Wizard function of the insulin pump takes into account the number of 
carbohydrates that are entered into the database of the CSII technology, along with blood 
glucose levels (Medtronic, 2009). The input of this information allows the technology to 
formulate an adjusted insulin administration dose based off of the data entered by the 
user. Prior to the initiation of the QIP, the combined average use of the BW by QIP 
participants was 3.6 times daily. Three months post-QIP, the combined average use of the 
BW by participants increased to 3.8 times daily.  
The override function of the insulin pump allows for the user to change the insulin 
administration that the BW has suggested from the formulation of the carbohydrate and 
blood glucose levels the user inputs into the database. Overriding the suggestions made 
by BW may indicate a knowledge deficit by the user or the misunderstanding of how to 
properly use the CSII technology (Medtronic, 2009). Prior to the initiation of the QIP, the 
combined average use of the OR function was 14%. Three months post-QIP the 
combined participant average use of the OR function decreased to 10.3%. 
Although the sample size was small, with only 26 participants in the QIP, and 
statistically two of the categories failed to significantly improve, the evaluation did 
provide proof that nurse-led education can improve patient outcomes. I recommend 
further study with a larger population of participants to delve deeper into the positive 
effects nurse-led education has on PLWD, as well as a number of other chronic illnesses. 
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Second, I recommended that each PLWD who is initiated on CSII therapy be 
provided education on the advanced technology of this treatment modality. This 
education can be provided in individual or group settings and should consist of multiple 
sessions. Upon conclusion, participants should able to demonstrate back to the instructor 
what was learned. By providing intensive nurse-led educational sessions, knowledge gaps 
PLWD may have regarding the advanced technology can be identified and closed, and 
overall outcomes can improve.   
Strengths and Limitations of the Project 
 Strengths associated with this DNP project include the positive outcomes noted 
through the evaluation process. Although the data for two of the categories was not 
statistically significant, review of the Trend Report did show improvement in all three 
categories evaluated, along with a 1.0% average drop in HgA1c of the participants. This 
information allowed the diabetic clinic to improve guidelines and begin to develop new 
protocols that will be followed at the initiation of CSII therapy and beyond. Of course, 
further study with a larger sample population is needed to delve into the positive effects 
nurse-led education can have on patient populations with chronic illness.  
 Limitations associated with this DNP project are the small sample size of 
participants and length of the QIP. When a sample size is small, it is more difficult to 
discern whether improvement is due to random chance or if the improvement is related to 
the intervention implemented (Grove, Burns, & Gray, 2013). Also, as this diabetic clinic 
works with only an adult population, the QIP was only provided to people older than 18 
years of age. Children, who make up a large portion of PLWD, were not evaluated.  
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Summary 
 Although the evaluation of the QIP had variable success statistically, all four 
categories that were evaluated demonstrated improvement post-education. The most 
impressive improvement was in the HgA1c levels with a reduction of 1.1. This reduction 
is significant as demonstrated by UKPDS study. Formulation of continued nurse-led 
patient education programs is critical to the success in the management and use of the 
advanced CSII technology and positive patient outcomes. Further study on this subject is 
warranted allowing for closure in knowledge deficits and clearer understanding for both 
the user and provider of these advanced technologies. 
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Section 5: Dissemination Plan 
 Disseminating evidence into practice involves a planned process that focuses on a 
target population and transfers knowledge from research into practice (Wilson, Petticrew, 
Calnan, & Nazareth, 2010). According to Marin-Gonzalez et al. (2017), dissemination is 
essential for communicating and implementing research findings, drawing focused 
attention to stakeholders involved in the study, and clearly displaying the research 
outputs. The purpose of evidence-based research is to strengthen baseline knowledge 
with improved guidelines and protocols through dissemination of evidence. This crucial 
element in research is the backbone of modern medicine and improved patient outcomes. 
The AACN put forth the Essentials for Doctoral Education for Advanced Nursing 
Practice to transform and change education required for advanced practice nursing 
(AACN, 2006). This education is focused on the translation of evidence into practice 
promoting best outcomes through the expansion of scientific knowledge (AACN, 2006).  
 The findings from this project will be used to better understand the behavior of 
the patients in the diabetic clinic that use CSII therapy. As this treatment modality 
continues to have technological advances, it is pertinent that patient education be at the 
forefront from initiation through continuation of this therapy. I discussed the findings of 
this project in detail with the director of the clinic, as well as the nurse practitioners and 
medical staff. Although the EB-QIP consisted of a small population of patients in this 
clinic setting, it provided great insight into the behavioral mechanisms between 
compliance and complacency.  
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 The dissemination of the project’s findings will be ongoing in the diabetes clinic. 
Discussions with educators from Medtronic have also commenced about designing new 
protocols for PLWD who are being considered candidates for CSII therapy. From the 
dissemination of the information obtained through the evaluation of the QIP, a few 
different protocol designs are being drafted to be presented to the director of the clinic for 
review. It is believed that when one of the providers in the clinic identifies a PLWD who 
is a candidate for CSII therapy, the candidate should be educated on the pathophysiology 
of diabetes, carbohydrates, dietary intake, and treatment options. It has been discussed 
that education sessions should be broken into multiple sessions, so as not to overwhelm 
the participants, and to provide a broad overview of diabetes and describe the 
commitment that is required from both the PLWD and the provider.  
Analysis of Self 
Analysis as Practitioner 
 This section is interesting, as it makes me look within and describe how I view 
myself. It is similar to looking in a mirror and examining the image that looks back at 
you; often criticizing shortfalls. The past 14 years have been a journey; one that I knew 
would end, but that end was so far in the distance I could barely see it.  
 My role as a practitioner is, and continues to be challenging, exciting, exhausting, 
frustrating, and rewarding. This position comes with many feelings that can become 
muddled. My daughter is completing her degree in psychology and one day was telling 
me about the “imposter” syndrome. This syndrome can be described as a person’s 
inability to outwardly show their accomplishments, always in fear of being exposed as a 
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fraud (Sakulku & Alexander, 2011). There are many times that I have felt this ‘imposter’ 
syndrome. I am forever educating myself, but most often I feel that there is still so much 
to learn so I can be up-to-date on the best practice principles to provide the best care 
possible to my patients. I also have become very humbled in this field of medicine, as I 
have come to realize that I am the only resource for some of my patients. As such, I have 
reached the understanding that I must always continually grow and learn in my position 
as a practitioner.  
Analysis as Scholar 
 My development as a scholar has been an interesting journey. I have learned so 
much through the development of this project. My understanding about research is much 
greater after having had the opportunity to develop a project from the ground up and see 
the difficulties and challenges that are faced. I did not go into nursing to be a researcher, 
but have slowly realized through this educational process that we are all scholars. It is so 
very important that I keep striving to learn the best possible ways to deliver care, and this 
can only be done through research and the development, by way of evaluation and 
dissemination, of best evidence-based practice principles. I definitely see myself growing 
as a scholar and delving deeper into nursing research. It is through the DNP role that the 
stage is set to apply research findings into the practice setting. Through the translation of 
evidence-based research, protocols can be changed and improved upon. Often the 
research is published, however, it is not always applied in the correct setting where it 
would be of greatest benefit. My future interests will involve diabetes care and nurse-led 
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education, developing new protocols for educating PLWD to improve the outcomes of 
complications related to the disease.  
Analysis as Project Manager 
 As project manager, there were many challenges I faced. The main challenge was 
getting the appropriate help from the staff. This included the extraction of the de-
identified data that I needed. As this is a very active diabetic clinic most days, the staff is 
extremely busy. Finding the time to help get me the necessary information was difficult. I 
did find that I would mostly rely on one or two specific staff members to help with me 
with this part of the project.  
 My ownership in the project did grow with the role of the project manager, 
leading to a stronger leadership role within the organization. I found that I had become 
very detailed in the tasks at hand and found myself directing the staff through daily goals. 
It is very important as a leader to respect your staff and have them respect you. I found 
that, even through the most stressful moments, I was stronger in leading, providing 
positive reinforcement, and encouraging the staff to become part of the project. This 
provided great initiative, and I found that many of the staff members who appeared 
disconnected to my needs as project lead started asking how they could help.  
Challenges, Solutions, and Insights 
 Becoming a nurse was a goal of mine for as long as I can remember, and with this 
goal came many challenges. Now that I am crossing the finish line of my education, 
having gone as far as I can scholastically in nursing, I reflect on the many challenges I 
have faced, most recently through the completion of this DNP project. The first challenge 
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I encountered was really understanding what the DNP project was. It took me a very long 
time to understand ‘what’ my goals and objectives were, as I felt that there were many 
loose ends that needed to be tied up. However, I was unsure how to ‘tie’ them together. It 
was only through hours of reading and rereading my proposal that the solution to this 
challenge appeared. The solution to many challenges in life is reaching out for necessary 
guidance. As such, I am grateful to my peers and instructors who helped me understand 
the path of my project. 
 Over the past three years, I have grown immensely, finding ways to overcome 
significant stress and anxiety when faced with situations that were difficult to understand. 
I have reexamined my potential as a scholar over and over again throughout the past year, 
questioning my ability to truly get to the end of this project. These struggles have made 
me stronger, knowing that as long as I set your sights on what is most important, I can 
accomplish whatever I set my mind to.  
In many ways, I look at the completion of my doctoral studies and my DNP 
project as finishing a marathon. I have had the pleasure of running two full marathons in 
my life. The start of the marathon is exhilarating; wondering if you can accomplish such 
a feat. The moment you cross the finish line, worn down emotionally and physically, the 
emotions that you feel are indescribable. You are overcome with a feeling of great 
accomplishment, both physically and mentally, along with the feeling of overwhelming 
joy and gratitude that your body and mind carried you through. This is the same 
indescribable feeling I have about completing this DNP project and completing my 
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doctoral studies. It has been a marathon to complete these past three years, and my 
feeling of accomplishment cannot be described in words.  
 The success of this project, however, was only achieved with the help of many 
others. I learned very quickly that attempting anything alone is never as fulfilling as 
having others work with you. Without the guidance of my committee chair and members, 
my project would not be where it is today. My committee chair has been my advocate 
and educator, teaching me the important steps in becoming a true scholar. Without her 
and every person involved in this project, I would not be where I am today. The main 
lesson learned has been understanding the importance of each person involved and 
knowing when to ask questions.   
Summary 
 Diabetes continues to be a growing problem in the United States and worldwide, 
affecting 415 million people. It is the sixth leading cause of disability (Chatterjee, Khunti, 
& Davies, 2017). The global economic burden, according to Chatterjee, Khunti, & 
Davies (2017), is estimated at $825 billion. There are numerous treatment options 
available for PLWD including oral glycemic agents, MDI therapy, and CSII therapy. The 
technological aspects of CSII therapy are advancing so rapidly, providing the most state-
of-the-art options for the treatment of diabetes, that PLWD and providers are left 
scrambling to keep up.  
Literature suggests that CSII therapy is superior to MDI therapy in reducing the 
amount of daily insulin use, hypoglycemic episodes, and improving quality of life for 
PLWD. The literature, however, did not provide substantial evidence about advanced 
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technological education provided to PLWD and the use of CSII therapy. Deeb et al. 
(2015) did, however, find that frequent use of the Bolus Wizard and blood glucose log 
features of the insulin pump did have a favorable effect associated with glycemic control. 
Much of the literature suggested that nurse-led education focusing on self-management 
skills demonstrated an improvement in self-efficacy/management for PLWD.  
The purpose of this DNP project was to evaluate the impact of a nurse-led 
educational program on glycemic control. This program was designed to identify whether 
or not the provision of advanced technological training for CSII therapy provided 
improvement in the understanding of the CSII technology for PLWD. It was the premise 
of the QIP project to improve technological understanding, thereby improving HgA1c 
levels of the participants post-education. 
Upon evaluation of the statistical data, it was evident that all four categories that 
were evaluated improved. Although this QIP project had a small number of participants 
(N=26), it did show that, with additional education, there was improvement in the 
usability of the CSII technology. Through these observations, the diabetic clinic is 
working closely with the representatives from the insulin pump manufacturers that are 
used most frequently in the clinic to develop an educational protocol for the initiation of 
CSII therapy, along with continued nurse-led education for PLWD. 
It is, however, recommended that this specialized arena of nurse-led diabetes 
education be further studied with a larger population of PLWD. With the advancements 
in technology, it is a failure of the medical community if providers, and users of these 
advance technological modalities to treat chronic illness, are not thoroughly trained on 
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the functionality of the technology. To continue to develop advanced treatment options 
for PLWD and not offer appropriate education on the operation of the equipment, 
effective glycemic control will be lost in confusion and the treatment will continue to be 
misunderstood.  
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Appendix A: Summary of Educational Sessions 
Self-Management/CSII (Insulin Pump) Patient Education 
Session 1/Day 1 -
Introduction 
• Introduction to the program. 
• Download Insulin Pump 
• Review most recent serum lab values with participant (HgA1c, C. 
Peptide, Fasting insulin/blood glucose) 
• Review categories of Trend Reports (Adherence report, Logbook 
report, Device settings report, Daily detail report) 
• Review Adherence report with participant. 
• Correlate serum lab values with data entries in Trend reports. 
Session 2/Day 2 
• Review previous session’s discussion and answer questions. 
• Review insulin pump download and Trend report categories ~ 
Review Logbook report in detail. 
• Discuss self-management skills to improve compliance with 
Logbook entries i.e., carbohydrates/blood glucose levels. 
• Discuss carbohydrate in greater detail. 
• Discuss physical activity and nutrition and their effect on blood 
glucose levels. 
• Answer questions/concerns from the participant 
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Session 3/Day 3 
• Download Insulin Pump ~ review most recent lab values with 
participant. 
• Review categories of Trend Reports ~ focus on reports from the 
download that participant has questions on. 
• Review self-management skills that the participant is struggling with. 
• Provide educational reference material that was discussed at previous 
sessions with the participant at the end of the session. 
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Author, 
Title, 
Journal 
Year Purpose Findings Population Type of 
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Primary or 
Secondary 
How does this help 
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Ghazanfar, 
H., Rizvi, 
S. W., 
Khurram, 
A., Orooj, 
F., & 
Qaiser, I. 
(2016). 
Impact of 
insulin 
pump on 
quality of 
life of 
diabetic 
patients. 
Indian 
Journal of 
Endocrinol
ogy and 
Metabolism
, 20(4), 
506-511. 
http://dx.do
i.org/10.41
03/2230-
8210.18347
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2015 
Identifying the 
impact of 
continuous 
subcutaneous 
insulin infusion 
(CSII) therapy 
on the quality 
of life in 
patient with 
type 2 diabetes 
mellitus 
(T2DM) and 
compare it to 
the quality of 
life of patient 
with T2DM 
using multiple 
daily injection 
(MDI) therapy.  
The use of 
CSII therapy 
improved 
quality of life 
such as self-
esteem, 
decreased 
stress and 
overall 
improved 
mood. Also, it 
improved 
physical 
health, 
flexibility in 
mealtime, as 
well as ease of 
travel. Those 
patients who 
shifted from 
MDI therapy 
to CSII 
therapy 
showed a 
significant 
(P<0.005) 
decrease in 
insulin 
requirement 
from 1.7 + 0.9 
to 1.1 + 0.6 
U/kg/day. 
Hypoglycemic 
episodes were 
also reduced in 
81.1% of the 
participants, 
which may be 
accounted for 
in the 
reduction of 
insulin 
requirement.  
Male/Femal
e age >50, 
with T2DM 
diagnosis >6 
months 
requiring 
use of 
insulin 
therapy  
Case-control 
study 
Primary 
 
Key Words: 
Insulin, quality 
of life, T2 DM, 
insulin pump, 
multiple daily 
injection therapy 
 
Grade 
Level III;  
Well-designed 
case control not 
randomized  
  
This study identifies the 
importance of utilizing 
advanced technology to 
optimize glycemic control. 
With glycemic control the 
development of complications 
associated with diabetes 
mellitus can be reduced. Also, 
with the use of CSII therapy it 
was found that the participants 
in the study experienced fewer 
episodes of hypoglycemia, 
improving overall quality of 
life.  
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(2013). 
Improveme
nt of b-cell 
function 
after 
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glycemic 
control via 
long-term 
continuous 
subcutaneo
us insulin 
infusion 
therapy in 
non-newly 
diagnosed 
type 2 
diabetic 
patients 
with 
suboptimal 
glycemic 
control . 
Diabetes/M
etabolism 
Research 
and 
Reviews, 
29, 473-
482. 
http://dx.do
i.org/10.10
02/dmrr.24
16 
 
2013 Identify the 
efficacy of B-
cell restoration 
in with the use 
of CSII therapy 
in non-newly 
diagnosed 
T2DM 
In non-newly 
diagnosed 
T2DM there 
was noted to 
be significant 
improvement 
in B-cell 
production 
with achieving 
optimal 
glycemic 
control with 
CSII therapy. 
After 6 months 
of CSII 
therapy 
(P<0.001) 
glycated 
hemoglobin 
A1c (HbA1c) 
was decreased 
from 8.7% at 
baseline to 
6.3%, and 
during the 
subsequent 24 
months 
median 
HbA1c levels 
were 
maintained 
between 6.3% 
and 6.5%.  C. 
Peptide levels 
also began to 
raise after 12 
months of 
CSII therapy.  
Patients 
with T2DM 
diagnosed 
>1 year, 
with HbA2c 
level of 
>7% despite 
previous 
treatment, 
absence of 
renal 
impairment 
prior to CSII 
therapy, and 
available for 
follow-up 
for at least 6 
months after 
initiation of 
CSII 
therapy.  
Retrospective 
Study ~ Case 
Report 
 
Grade 
 
Level IV; No 
groups to 
compare 
Primary   
This study provides insight 
into the promotion of 
improved B-cell function in 
T2DM with the utilization of 
CSII therapy and 
improvement of glycemic 
control. With a reduction of 
HbA1c levels from baseline of 
8.7% to 6.3%, it was found 
that the C. Peptide levels also 
improved within a 12-month 
period.  
Deeb, A., 
Abu-Awad, 
S., Abood, 
S., El-
Abiary, M., 
Al-Jubeh, 
2015 This study was 
designed to 
assess the 
association of 
various key 
elements of 
The frequency 
of blood 
glucose 
control 
monitoring 
and the use of 
T1DM 
consisting 
of children 
with median 
age of 12 
and adults 
RCT 
 
 
Secondary 
 
Key words: 
T1DM, CSII 
  
This study provides 
significant information 
regarding the use of key 
features of CSII technology 
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diabetes 
control in 
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pump 
therapy in 
patients 
with type 1 
diabetes 
mellitus. 
Diabetes 
Technology 
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Therapeuti
cs, 17(3), 
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http://dx.do
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insulin pump 
functions and 
their effect on 
blood glucose 
control 
the Bolus 
Wizard had 
favorable 
association 
with glycemic 
control, which 
was more 
significant in 
the children’s 
groups. More 
significant, 
however, those 
patients who 
used the bolus 
feature of the 
CSII 
technology 
had better 
glycemic 
control. 
with a 
median age 
of 27.5.  
 
 
 
 
Grade 
Level II; 
Well-designed 
RCT 
 
therapy, insulin 
pump, bolus, 
glycemic control 
and the improvement in 
glycemic control. It also 
identifies that human behavior 
has a significant role in the 
use of CSII therapy and 
glycemic control outcome.  
Reznik, Y., 
Cohen, O., 
Aronson, 
R., Conget, 
I., Runzis, 
S., 
Castaneda, 
J., & Lee, 
S. (2014). 
Insulin 
pump 
treatment 
compared 
with 
multiple 
daily 
injections 
for 
treatment 
of type 2 
diabetes 
(OpT2mise
2014 This study was 
comparing the 
difference 
between MDI 
and CSII 
therapy and the 
optimization of 
glycemic 
control. The 
OpT2mise 
study was 
designed to 
define the 
specific role 
CSII therapy 
had on T2DM 
and to define 
safety, rate of 
hypoglycemia, 
patient 
adherence, and 
patient 
495 patients 
were entered 
into the run-in 
phase of the 
study, with 
331 
participants 
randomized. 
168 
participants 
were started 
on CSII 
therapy, 
whereas 163 
were 
continued on 
MDI therapy. 
Baseline 
HbA1c was 
9% for both 
groups. The 
study was 
T2DM 
patients 
with poor 
glycemic 
control 
despite MDI 
therapy, age 
30-75, male 
and female 
~ Exclusion 
pregnancy 
or a 
maximum 
daily dose 
of insulin 
220 units.  
RCT 
 
 
 
 
Grade 
Level II;  
Well-designed 
RCT 
 
Primary   
This study provided 
significant statistical data 
proving that optimization of 
glycemic control can be 
obtained through the use of 
CSII therapy safely in T2DM 
patients, with a reduction in 
TDD of insulin.  
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): a 
randomized 
open-label 
controlled 
trial. 
Lancet, 
384, 1265-
72. 
http://dx.do
i.org/10.10
16/S0140-
6736(14)61
037-0 
 
satisfaction. conducted 
over a 6-
month period 
after which the 
CSII group 
had a 
reduction in 
HbA1c of 
1.1% in 
comparison to 
the MDI group 
which had a 
reduction of 
0.4%; the 
mean 
difference 
between the 
two groups 
was 07%. The 
CSII group 
used a mean 
total daily 
dose (TDD) of 
insulin of 97 
units, where 
the MDI group 
used a mean 
TDD of 122 
units of insulin 
(P<0.0001). 
There was no 
significant 
body weight 
difference 
between the 
groups.  
Weissberg-
Benchell, 
J., 
Antisdel-
Lomaglio, 
J., & 
Seshadri, 
R. (2003). 
Insulin 
pump 
therapy. 
Diabetes 
Care, 26, 
1079-1083. 
2003 This study was 
conducted to 
identify the 
metabolic and 
psychosocial 
impact on 
children and 
adults with the 
use of CSII 
therapy. 
The study 
findings proved 
that CSII 
therapy was 
associated with 
improved 
glycemic control 
when compared 
to MDI therapy. 
Also, it was 
found that the 
utilization of 
CSII therapy 
was not 
associated with 
any adverse 
As this was 
a meta-
analysis 
there were 
52 studies 
included in 
the analysis 
with a total 
of 1,557 
subjects 
with T1DM, 
adult and 
pediatric.  
Meta-analysis 
 
Grade 
Level I; 
Evidence 
from a 
systematic 
review 
Primary 
 
Key Words: 
T1DM, T2DM,  
CSII therapy, 
MDI therapy, 
glycemic 
control, 
hypoglycemia, 
insulin 
resistance, 
psychosocial, 
  
Conclusions exhibited through 
this study was that CSII 
therapy is correlated with 
improvement in glycemic 
control, thus providing 
additional support in 
preventing chronic conditions 
associated with diabetes. 
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outcomes  behavior. 
Li, F., Fu, 
L., Zhang, 
W., Su, X., 
Wu, J., 
Sun, J., ... 
Ma, J. 
(2016). 
Blood 
glucose 
fluctuations 
in type 2 
diabetes 
patients 
treated with 
multiple 
daily 
injections. 
Journal of 
Diabetes 
Research, 
2016. 
http://dx.do
i.org/10.11
55/2016/10
28945 
 
201
6 
This study was 
conducted to 
compare 
fluctuations in 
blood glucose 
levels in 
T2DM 
participants 
treated with 
three different 
therapies; CSII 
therapy, MDI3 
(3 injections 
daily), and 
MDI4 (4 
injections 
daily). 
CSII therapy 
proved to 
promote the 
most improved 
glycemic control 
faster than MDI 
therapy (4.26 + 
1.88 days) in the 
CSII group 
versus (6.17 + 
2.36 days) 
MDI3 group, 
and (581 + 2.46 
days) MDI4 
group. CSII 
group (P < 0.05) 
versus MDI3 
and MDI4 
groups. Also, 
the longstanding 
T2DM group 
fared better on 
CSII therapy 
versus MDI3/4 
therapy (P < 
0.05) for CSII 
group.  
T2DM 
patients 
newly 
diagnosed 
and 
longstandin
g T2DM, 
age 18-80, 
with HbA1c 
of 12%, 
male/female
.  
Randomized, 
parallel group 
trial. 
 
 
 
Grade 
Level II; 
Well-designed 
RCT 
Secondary 
 
 
Key words: 
MDI therapy, 
CSII therapy, 
Insulin pump, 
Behavior, 
T2DM, T1DM, 
glycemic control  
  
This study focuses on the 
improvement in glycemic 
control with the use of CSII 
therapy in T2DM patients 
who are not controlled on 
MDI therapy. Unfortunately, 
further study is needed to 
examine the risks of CSII 
therapy focusing on the 
psychological impact of 
utilizing this technology, 
along with future 
advancements associated with 
the technology and patient 
adherence 
Maia, M. 
A., Reis, I. 
A., & 
Torres, H. 
D. (2016). 
Relationshi
p between 
the users’ 
contact 
time in 
educational 
programs 
on diabetes 
mellitus 
and self-
care skills 
2016 This study was 
performed to 
identify the 
relationship 
between users’ 
contact hours 
in educational 
program and 
self-care 
knowledge 
variables in the 
relation to 
diabetes 
mellitus. 
A final group 
of 151 users 
were included 
in the study. It 
was found that 
there was 
significant 
improvement 
in self-care 
scores 
(P<0.05) for 
those users 
during the 
educational 
interventions, 
which 
Type 2 DM 
patients, 
male/female
, ages 30-85. 
Longitudinal 
descriptive 
study 
 
Grade 
Level VI; 
Evidence 
from a single 
descriptive 
study 
Secondary 
 
Keywords: 
Health 
education, 
diabetes 
mellitus, 
knowledge, self-
care, nursing.  
  
This study highlights the 
benefits of patient education 
and the promotion of self-care 
and knowledge enhancement 
and understanding of diabetes. 
It is interesting to note that the 
151 participants in this study 
gained improvement in both 
self-care qualities (P<0.05), 
as well as baseline knowledge 
at the conclusion of the 
educational program. 
86 
 
and 
knowledge. 
Journal of 
Nursing, 
50(1), 59-
64. 
http://dx.do
i.org/10.15
90/S0080-
623420160
000100008 
consisted of 8 
hours. 
Knowledge 
base also 
increased for 
the users.   
Wu, S. V., 
Liang, S., 
Lee, M., 
Yu, N., & 
Kao, M. 
(2013). The 
efficacy of 
self-
manageme
nt 
programme 
for people 
with 
diabetes, 
after 
special 
training 
programme 
for 
healthcare 
workers in 
taiwan: a 
quasi-
experiment
al design. 
Journal of 
Clinical 
Nursing, 
23, 2515-
2524. 
http://dx.do
i.org/10.11
11/jocn.124
40 
2013 This study was 
performed to 
analyze the 
efficacy of 
improving 
disease 
management 
after 
implementing a 
self-
management 
program for 
people with 
T2DM. 
There were (n 
= 147) 
participants in 
the 
experimental 
group and (n = 
81) in the 
control group. 
Post test 
scores of BMI 
(P < 0.01), 
waistline 
circumference 
(P< 0.01),  
Hba1c 
(P<0.001) and 
depression/anx
iety 
(P<0.001)in 
the 
experimental 
group versus 
the control 
group. Post-
test scores for 
self-efficacy 
(P,0.001) for 
the 
experimental 
group.  
T2DM, 
male/female
, > 20 years 
of age.  
Quasi-
experimental 
design 
 
 
Grade 
Level III 
Secondary 
 
 
Keywords:        
T2DM, self-
management, 
self-care, 
education,  
  
This study highlights that 
people living with diabetes 
can effectively improve self-
efficacy with planned 
implementation of self-
management training 
programs with trained 
healthcare workers. This 
illustrates that with continued 
diabetes education promoting 
self-care habits and 
understanding, improvement 
in factors associated with 
diabetes and the chronicity of 
the disease can be reduced, 
thus reducing risk factors for 
multiple other complications 
associated with diabetes.  
Fitzpatrick, 
S. L., 
Schumann, 
K. P., & 
2013 The purpose of 
this study was 
to examine the 
published 
There was a 
large variance 
in the studies 
and their 
Sixteen 
intervention 
randomized 
controlled 
Systematic 
Review 
Secondary 
 
  
This systematic review 
focused on educational 
87 
 
Hill-
Briggs, F. 
(2013). 
Problem 
solving 
interventio
ns for 
diabetes 
self-
manageme
nt and 
control: A 
systematic 
review of 
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literature. 
Diabetes 
Research 
and 
Clinical 
Practice, 
100, 145-
161. 
http://dx.do
i.org/10.10
16/j.diabres
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6 
literature on 
the effect of 
problem-
solving 
interventions 
on diabetes 
self-
management 
and disease 
control. 
approaches to 
problem-
solving in 
patient 
education. It 
was found, 
however, that 
with education 
regarding 
problem-
solving 
interventions 
36% of the 
adults who 
participate in 
the study and 
42% of 
children who 
participated in 
the study 
showed 
significant 
improvement 
in HbA1c. 
Psychosocial 
outcomes have 
been more 
promising.  
trials (11 
adults, 5 
children/ado
lescent) and 
8 
intervention 
studies that 
were quasi-
experimenta
l designs (6 
adult, 2 
children/ado
lescent) 
consisting 
of 
T1DM/T2D
M, 
Male/female  
 
Grade 
Level I 
Keywords:  
Diabetes 
mellitus, 
problem-
solving, problem 
focus, decision 
making, self-
management, 
education, self-
care 
interventions and the positive 
aspects associated with the 
use of patient education as a 
positive intervention in 
improving glycemic control, 
and promoting self-
management/self-care 
attributes. With continued 
patient education, chronic 
conditions associated with 
uncontrolled diabetes can be 
reduced, allowing patients to 
feel empowered over the 
course of their diagnosis of 
diabetes. 
Wilkinson, 
A., 
Whitehead, 
L., & 
Ritchie, L. 
(2014). 
Factors 
influencing 
the ability 
to self-
manage 
diabetes for 
adults 
living with 
type 1 or 2 
diabetes. 
Internation
al Journal 
of Nursing 
Studies, 51, 
111-112. 
http://dx.do
2014 This study was 
looking at 
barriers/influen
ces that 
influence self-
management/se
lf-care for 
adults with 
types 1 and 2 
diabetes 
mellitus 
In this 
systematic 
review there 
were multiple 
barriers that 
were 
associated 
with the day-
to-day 
management 
of diabetes. 
The key issues 
related to 
communicatio
n, education, 
personal 
factors, 
providers’ 
issues. 
Interestingly, 
communicatio
n with 
Adults 
living with 
types 1 and 
2 diabetes 
mellitus. 
Systematic 
Review 
 
Grade 
Level I 
Secondary 
 
Keywords: 
Barrier, T1DM, 
T2DM, 
facilitators 
qualitative 
research, self-
care, systematic 
review 
  
This study focuses on the 
importance of diabetes 
education concentrating on 
self-care. It also highlights the 
importance of communication 
between provider and patient, 
as well as the provision of 
culturally sensitive care. With 
good communication between 
the provider and patient, 
patient compliance will 
improve  It is important to 
understand that this study also 
find that community support 
played a significant role in 
patient’s ability to self-
manage their diabetes, as there 
are many issues patients face 
day-to-day, compounded with 
vulnerability increasing 
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providers, 
along with 
educational 
programs that 
provided 
appropriate 
skills to be 
successful in 
self-care was a 
significant 
barrier, along 
with the 
provision of 
culturally 
sensitive care 
situational, cultural and social 
issues. Diabetes is variable, 
affecting each person 
differently and as such, self-
care needs to be individually 
addressed meeting each 
persons’ life experiences.  
